

Index

Note: page numbers in *italics* refer to figures and tables

- abdominal surgery, ejaculation
abnormalities 457–58
- abortion, spontaneous 284, 364, 365
- accessory glands
secretions 582
spinal cord injuries 465–66
- L-acetylcarnitine 433–34
- acetylcholine in erectile function
137–38
- acrosin 110, 112, 180
immunocontraception 485
- acrosomal exocytosis (AE) 104, 108,
110–11
calcium ions 111
disordered 104, 113
follicular fluid 111
gamete fusion prerequisite 112
progesterone 111
protein tyrosine phosphorylation
111
SNARE proteins 111
in vitro 113
see also acrosome reaction
- acrosomal proteins 485
- acrosomal status, impaired 502–03
- acrosome 74
abnormalities 577–78
absence 179
formation 80
loss 110–11
- acrosome reaction 582–83
capacitation process 582–83
insufficiency 180–81
prematurity 180–81
spontaneous 180
stimulants 180, 181
see also acrosomal exocytosis (AE)
- acrosome reaction assay 171, 180–82
stimulated 181
- actin filaments, Sertoli cells 50–51
- activator of CREM (ACT) 83–84
- ADAM proteins 112
- adenine nucleotide transporter
(ANT) 37
- adenosine monophosphate, cyclic *see*
cAMP
- adenylate cyclase 106
- stimulation 139–40
- adherens junctions, Sertoli cells 56
- adolescents, varicocele 340–41
- adrenomedullin 333
- adult polycystic kidney disease 179
- age/aging
chemical exposure 229
free radicals 39
ICSI outcome 504–05
intrauterine insemination 495–96
Leydig cells 38–40
LH levels 38–39
oxidative stress 39
stem Leydig cells 34
testicular biopsy 223
testosterone levels 29, 38–39
decline of circulating 206, 207
- AID *see* donor insemination
- AIDS *see* HIV infection
- alcohol consumption 157
causing male infertility 431
chemical exposure 229–30
gonadotoxicity 241
- alfuzosin 459
- allopurinol, gonadotoxicity 240
- alpha-adrenoceptor agonists,
ejaculation abnormality
management 459
- alpha-adrenoceptor antagonists 156
competitive nonspecific 140
ejaculation abnormalities 459
gonadotoxicity 238
- alpha-adrenoceptors 140
erectile function 136
- American Society for Reproductive
Medicine (ASRM), guidelines
for sperm donation 597–98
- American Society of Clinical
Pathologists (ASCP), sperm
morphology classification 561,
574
- amniotic cavity 1
- amphetamines, gonadotoxicity 241
- amplicons 253–54
- amygdaloid nucleus, medial 144
- anabolic steroids 156, 237–38
testicular biopsy 223
- anastrozole 443
- androgen(s) 257
anabolic steroids 237–38
biosynthesis 256–57
defects 256–57
deficiency diagnosis 206–07
empiric therapy 445, 446–47
exogenous 156
exposure during development 262
hypothalamic–pituitary–gonadal
axis requirement 439
imbalance 157
immune regulation 281
oral 446–47
requirements for male
reproduction 257
role 256
synthetic 446
testicular descent 262
- androgen insensitivity 258–60
complete 205–06, 258
partial 258
clomiphene citrate
therapy 442
- androgen insensitivity syndrome,
minimal 258–59
- androgen receptor(s) 257
CAG length 259
defects 205–06, 259
gene deletion 258
glutamine polymorphisms 259
spinal and bulbar muscular
atrophy 259
testosterone regulation of
spermatogenesis 257–58
- androgen receptor knockout mice
(ARKO) 61, 83
- androgen replacement,
nonprescription drugs 209
- androgen resistance 205–06
diagnosis 206
partial 205–06
- androgen-binding protein, Sertoli cell
secretion 62–64
- andropause, testicular biopsy 223
- androstenedione production in
Leydig cells 34–35

- androstosterone, progenitor Leydig cell production 32
- anejaculation/anemission 455–56
- anesthesia
- MESA 411
 - mini-MESA 411–12
 - PESA 412
 - sperm retrieval 408
 - TESA 414
 - TESE 412, 413
 - vasectomy 474–75
- aneuploidy
- frequency 189, 190
 - ICSI sperm 505–06
 - sperm FISH testing 188–91, 505–06
- Angelman syndrome 508–09
- angiotensin 141
- angiotensin-converting enzyme (ACE) 141
- animal husbandry AI research 493
- animal models of gene mutations 646
- anorgasmia 456
- anosmin 1 265
- antiandrogens 228
- DDT 234
 - medications 237
 - phthalates 236
- antibiotics
- gonadotoxocyt 238
 - history taking 157
 - leukocytospermia 318–19
- antibodies 279
- anatomy 280
 - function 280
 - production 282–84
 - types 280
 - see also* antisperm antibodies
- antibody-dependent cell-mediated cytotoxicity (ADCC) 278
- antibody-mediated immunity, tests 285
- antibody-mediated infertility mechanisms 284
- antibody-mediated sperm autoimmunity 282
- anticipation, genetic 259
- antidepressants
- ejaculation abnormalities 459
 - gonadotoxicity 240
- antiestrogen therapy 439–42
- antigen-presenting cells 277–78
- antigens 279
- antihistamines, leukocytospermia 320
- antihypertensive medications
- causing male infertility 430
 - gonadotoxicity 238
 - history taking 156
- anti-Müllerian hormone (AMH) 8, 90, 257, 421–22
- ovarian reserve measurement 371
 - persistent Müllerian duct syndrome 264
- antioxidants
- empiric therapy 449
 - leukocytospermia 319–20
 - semen
 - determination 624–25
 - enzymatic 624–25
 - nonenzymatic 625
 - total capacity measurement 625 - see also* reactive nitrogen species (RNS); reactive oxygen species (ROS)
- antisperm antibodies 162, 171, 279, 282
- circulating 607, 609, 610
 - detection assays 286
 - female 284
 - ICSI 610
 - outcome 506
 - success 289 - intrauterine insemination 287
 - leukocytospermia 315–16
 - linked conditions 283
 - post-vasectomy 283
 - production 282–84
 - sperm surface antibodies 609
 - vasectomy 222, 478
 - in-vitro fertilization success 288
- antisperm antibody tests 603–11
- clinical relevance 603
 - diagnostic 603–05
 - pitfalls 609–10
 - predictive value 609
 - proficiency testing 609
 - quality control management 608–10
 - recommendations 609–10
 - sensitivity/specificity 609
 - variability 608–09
 - see also* immunobead test (IBT)
- antispermatogenic compounds 486
- antral follicle count 371, 372
- anxiety 517–18
- apomorphine hydrochloride 139
- apoptosis
- germ cell loss 227
 - spermatocytes 79
 - testicular cells 227
 - varicocele 335
- apoptotic markers 637–38
- appendix testis 8
- arc sinevariance transformation 608
- area under the curve 542–43
- aromatase inhibitors 439, 442–43
- artificial neural networks (ANNs) 547–48
- artificial insemination
- with donor semen in
 - hypergonadotropic hypogonadism 205
 - history 493
 - see also* intrauterine insemination
- ascorbic acid, seminal 431
- aspermatogenic autoantigens 282
- aspermia 164
- assisted hatching 509
- assisted reproductive technologies (ART) 29
- adjunctive procedures 509–10
 - anxiety 517–18
 - birth defects 507–08
 - cost-effectiveness 509
 - DNA damage tests 187
 - experimental procedures 510
 - female age 365–66
 - guidelines 502
 - microsurgical reconstruction 403
 - model legislation 537–38
 - peritoneal factors in women 370–71
 - psychological issues 519–25
 - risks 507–09
 - stress 517–18
 - success rate 506
 - see also named techniques*
- asthenospermia 166–67
- algorithm 170
 - sperm transport failure 583
- astrozole 443
- autoimmune syndromes 277
- autoimmunity
- cell-mediated 284–85
 - cross-reactivity 282
- autonomic dysreflexia 460
- autonomic nervous system
- ejaculation 143
 - erection 134
- autonomic neuropathy, genitourinary 458
- autosomes, fertility genes 124
- axoneme formation 81
- azoospermia 162–63
- algorithm 165
 - chromosomal recombination 125–26
 - clomiphene citrate
 - effects 440
 - treatment 432 - congenital absence of vas deferens 377–78
 - DBCP exposure 233–34
 - epididymal obstruction 377
 - finasteride 237

Index

- azoospermia *cont.*
 genetic factors 251–56
 ICSI
 outcome 506–07
 sperm banking 599–600
 intrauterine insemination use 496
 IVF 599–600
 micro-TESE 416
 nonobstructive 162–63, 251–53
 obstructive 162, 163
 psychological issues 521
 sperm banking 599–600
 sperm retrieval 415–16
 testicular 412, 414
 synaptonemal complex 126
 testicular biopsy 221–22
 varicoectomy 353, 354, 355
 azoospermia factor (AZF) regions
 254–56
 deletions 416
 AZT 305–07
- basement membrane hyalinization 218
 basic helix-loop-helix (bHLH)
 transcription factors 57
 Bayes' theorem 547
 Beckwith–Wiedemann syndrome 508–09
 behavior, testosterone replacement
 therapy effects 209
 benign prostatic hyperplasia 99
 benzodiazepines 145–46
 beta-blockers, gonadotoxicity 238
 bioinformatics 628
 biomarkers of oxidative stress 628
 bivariate 547
 bladder
 embryology 6
 retrograde ejaculation 586
 bladder neck
 incompetence 457
 sphincter closure 143
 blastocyst 1, 2
 blood–testis barrier 55–56, 280
 chemical exposure 231
 tight junctions 55, 56
 bone marrow transplantation 156
 bromocriptine, empiric therapy 448
 Bryan–Leishman stain 316, 613
 Buck's fascia 132
 buffers
 semen processing 585
 sperm cryopreservation 595–96
 bulbocavernosus muscle 132, 143
 bulbocavernosus response, spinal cord
 injuries 461–62
 bulbospongiosus muscle,
 electromyographic activity 144
- bulbourethral glands 100
 ejaculation 143
 embryology 6
- cabergoline 433
 cadmium
 exposure with smoking 230
 varicocele 335
 caffeine consumption 157
 chemical exposure 229–30
 calcification, ejaculatory duct 381,
 425–26, 427
 calcitonin gene-related peptide
 (CGRP)
 erectile function 137–38
 urethra 143
 calcium channel blockers
 causing male infertility 430
 gonadotoxicity 238
 history taking 156
 calcium ion channels 136
 calcium ions
 acrosomal exocytosis 111
 intracellular
 erectile function 136
 sperm 107
 cAMP, steroidogenesis 35
 cAMP-dependent kinase anchoring
 proteins (AKAP) 81
 cAMP response element (CRE) 57
 cAMP response element binding
 protein (CREB) 57
 cAMP response element modulator
 (CREM) 83–84
 cancer/cancer treatment 156
 children's fertility preservation 532
 embryo cryopreservation 530
 environmental chemicals 226
 history 156
 insurance providers 537
 sperm collection for future
 insemination 598–99
 sperm cryopreservation 239, 529
 sperm retrieval 416–17
 caput epididymidis 91–92
 sperm motility 93
 carcinogenesis 228
 DNA adduction 227
 cardiovascular disease, vasectomy
 478–79
 carnitine 433–34
 leukocytospermia 319–20
 catalase 624
 catch-up growth 340–41
 cauda epididymidis 91–92
 sperm motility 93
 sperm storage 454
- cavernous nerve 135–36
 CD9, gamete fusion 113
 cell phones 240, 435
 cell-mediated autoimmunity, sperm
 284–85
 cell-mediated immunity 277–78
 cell types 278
 down-regulation 281
 mediators 278
 tests 285–86
 cell-mediated response 277
 cellular retinoic acid binding protein
 (CRABP) 65
 cellular retinol binding protein
 (CRBP) 65
 central limit theorem 542–43
 cervical mucus 104–05, 582
 periovulatory 582, 583
 sperm capacitation 105
 sperm interaction 171, 179–80
 sperm penetration 583
 cervix, female infertility 369
 chemical exposure 232–36
 age 229
 alcohol consumption 229–30
 antiandrogens 228
 blood–testis barrier 231
 caffeine consumption 229–30
 cancer 226
 carcinogenesis 227, 228
 cigarette smoking 230
 cumulative damage 229
 dosage 228–29
 threshold 229
 duration 228–29
 environmental 231–32
 estrogens 226
 estrogenic activity 227–28
 frequency 228–29
 history 226
 laboratory animal models 231
 lifestyle factors 229–30
 medications 236–40
 obesity 229
 occupational 231–32
 oxidative phosphorylation
 disruption 227
 phthalates 236
 polyhalogenated aromatic
 hydrocarbons 234–36
 potency 228–29
 risk assessment 231–32
 route 229
 sex hormone metabolic activation/
 inactivation 230–31
 short-chain aliphatic hydrocarbons
 232–34

- susceptibility influence factors 228–31
 testicular dysgenesis syndrome 228
 thresholds 228–29
 chemiluminescence assay 619, 627
 enhanced 625
 leukocytospermia 317
 protocol 625–26
 chemokines 623–24
 chemometrics 628
 chemotaxis in sperm 108
 chemotherapy 156
 gonadotoxicity 238–39
 sperm collection for future insemination 598
 sperm retrieval 416–17
 spermatogenesis recovery 239
 children
 fertility preservation 532–33
 illnesses 155
 varicocele 340–41
Chlamydia trachomatis 297–98, 431
 donor semen screening 597–98
 epididymitis 297
 epididymo-orchitis 431
 investigations 299
 pyospermia 167–68
 urethritis 295, 431
 cholesterol
 efflux from sperm 106
 steroidogenesis 35
 testosterone replacement therapy effects 209
 transport 36
 by StAR 36, 37
 transport molecules 35–38
 choriocarcinoma, imaging 384
 chromatid body 84
 chromatin, sperm 185
 chromomycin A₃ 633, 636
 chromosomal recombination
 abnormal in male infertility 126
 azoospermia 125–26
 proteins 127
 variations in normal spermatogenesis 126–27
 chromosome abnormalities/
 anomalies
 assisted reproduction 508
 diagnosis 642–45
 female infertility 366, 367
 numerical 251–53, 643–45
 sperm FISH testing 188–91
 structural 253–56, 643–45
 chromosome microarrays 644–45
 chromosome painting 643, 644
 chromosome translocations
 reciprocal 190
 aneuploidy rate 189
 see also Robertsonian translocation
 chromotubation, ejaculatory duct
 obstruction 424
 cigarette smoking 157
 cadmium exposure 230
 causing male infertility 431
 chemical exposure 230
 seminal ascorbic acid levels 431
 cimetidine
 causing male infertility 430
 gonadotoxicity 240
 cislomiphene citrate 440, 441
 claudin 11, 56
 claudins 56
 cloaca 1, 2–6
 cloacal membrane 11
 separation 4–6
 clomiphene citrate 432, 439–42
 adjuvant following varicolectomy 354
 estrogenic effects 440
 side effects 440–42, 497
 cloning 510
 cocaine use 156
 gonadotoxicity 241
 cohesins 78
 colchicine, gonadotoxicity 240
 color-flow Doppler ultrasonography,
 varicocele imaging 338, 375,
 376–77
 colorimetric assay 625
 protocol 626
 comet assay 633, 637
 comparative genomic hybridization 643, 644
 complement-dependent cytotoxicity 603
 complete androgen insensitivity (CAIS) 205–06, 258
 computer-assisted semen analysis (CASA) 161, 563
 conception rate 362
 condoms, immunologic infertility 286
 confidentiality, gamete donation 522
 confirmatory tests 544
 congenital adrenal hyperplasia 262
 hypogonadotropic hypogonadism 203
 congenital androgen insensitivity syndrome (CAIS) 20
 congenital bilateral absence of vas deferens (CBAVD) 162, 164–65, 262–64
 cystic fibrosis genes 262–63, 457
 cystic fibrosis transmembrane receptor gene mutation 162, 377, 508
 diagnosis 378
 ejaculatory abnormalities 457
 ejaculatory duct obstruction
 differential diagnosis 423
 hypoplastic epididymis 410
 imaging 377–78
 MESA 410
 mesonephric duct differentiation failure 262, 264
 PESA 415
 physical changes 262
 renal agenesis 387
 sperm retrieval 409–10, 415
 ultrasonography 378
 congenital lipid adrenal hyperplasia (CLAH) 257
 consent *see* informed consent
 contraception, male 474
 epididymal factors 486
 hormonal 480–84
 immunocontraceptives 483–85
 nonhormonal 486
 see also vasectomy
 control, loss of (psychological) 519
 controlled ovarian hyperstimulation 500
 convertase 1
 coping styles 518
 corpus cavernosa 132
 arterial supply 132
 erectile tissue 133
 corpus spongiosum 132
 corticosteroids, immunologic
 infertility treatment 286
 corticotropin-releasing hormone (CRH) 24
 cortisol 333
 counting chamber 553–55, 556, 585
 couples
 donor gamete acceptance 523
 medical team consultation 519
 relationships 520
 Cowper's glands *see* bulbourethral glands
 cranial suspensory ligament 11
 cremasteric system, external 332–33
 cryopreservation
 biological system complexity 593
 principles 593
 techniques 594–97
 testicular tissue 594
 cryoprotective agents (CPA) 593, 595, 596

Index

- cryptorchidism 155, 260, 261–62
 cellular immune response 284
 imaging 382, 383
 sperm retrieval 417
 testicular biopsy 223
 tumor mass 383
- cyclic adenosine monophosphate *see*
 cAMP
- cyclic guanosine monophosphate
 (cGMP) 137
- cyclooxygenase 2 (COX-2) inhibitors,
 leukocytospermia 319
- cyclosporine
 gonadotoxicity 240
 immunologic infertility treatment
 287
- CYP17 35
- cyproterone acetate 482
- cystic fibrosis 262–63, 508
- cystic fibrosis transmembrane
 receptor (*CFTR*) gene
 mutations 263
 CBAVD 162, 262–63, 377, 457, 508
 ejaculatory duct congenital
 obstruction 393, 422
 epididymal obstruction 377
- cytochrome c reduction test 620
- cytochrome P450 (CYP450),
 disruption by DDT 234
- cytokines 279, 314–15
 autoimmune response 285
 immune tolerance 281
 ROS analysis 623–24
 spinal cord injuries 466
- cytomegalovirus (CMV) 303, 305
 donor semen screening 597–98
- cytometric bead array (CBA)
 623–24
- cytoplasmic transfer 510
- cytotoxic T cells 278
- dapoxetine, premature ejaculation
 treatment 146, 456, 459
- data analysis
 diagnostic tests 544–46
 outcome studies 546–48
 statistics 541–46
- Dax1* gene defect 265
- DAZ* gene 645–46
- DDE exposure 234–35
- DDT exposure 232, 234–35, 434–35
 CYP450 disruption 234
- decapacitating factors 583
- delayed ejaculation 456
- deleted in azoospermia (*DAZ*) gene
 645–46
- density gradient centrifugation 589
- depot medroxyprogesterone acetate
 (MPA) 482
- depression 517
- desogestrel 482
- detumescence 133, 134
- di(2-ethylhexyl)phthalate (DEHP) 236
- diabetes mellitus 155–56
 ejaculation abnormalities 458
 erectile dysfunction 458
 hypogonadotropic hypogonadism
 203
- diagnostic tests 544–46
- diagnostic thresholds/predictive
 values 544
- diaminofluorescein 2 assay 624
- diaminonaphthalene assay 624
- 1,2-dibromo-3-chloropropane
 (DBCP) 233–34
- dienogest 482–83
- diethylstilbestrol 156, 237
- dihydrotestosterone (DHT) 91, 199,
 256
 androgen replacement 209
- dipstick tests 613
- discontinuous gradient separation 589
- discriminant function analysis 547
- disomy 644
 normal men 188–89
 sex-chromosome numerical
 anomalies 189–90
- DNA adduction 227
- DNA breakage detection–fluorescence
 in-situ hybridization
 (DBD-FISH) 633, 637
- DNA damage
 assessment 623–24
 extratesticular factors 185
 origin 638
 pregnancy rate 185
 primary testicular factors 185
 reactive oxygen species 185, 638
 reproductive outcomes 185–87
 sperm 184, 185, 186
 spermatogenesis abnormalities 638
 testicular biopsy 220
 tests 187
 in-vitro fertilization 185–87
- DNA fragmentation
 ICSI outcome 506, 633
 measurement 633–38
 sperm retrieval 417–18
 sperm tests 633
 tests 637
 varicocele 334–35, 354
- DNA fragmentation index (DFI) 80,
 634–35, 636
- DNA instability 508
- DNA integrity testing 633–35, 636–38
 clinical relevance 636
 improving 636–38
- DNA mismatch repair 124
- DNA recombination
 abnormal in male infertility 126
 azoospermia 125–26
 errors 124
 proteins 127
 spermatogenesis 124–26
 variations in normal
 spermatogenesis 126–27
- DNA sequencing, direct 643
- donor backup 521
 medical team recommendations 523
- donor insemination
 donor screening 532, 536
 legal issues 531–32
 liability 536
 paternity issues 532
 psychological issues 523, 524
 record keeping 532, 536
- dopamine, ejaculation 145
- dopaminergic agonists 139
- Doppler examination, varicocele 337
- dorsal penile nerve 144
- Down syndrome 644
- drugs, illicit
 causing male infertility 430
 gonadotoxicity 241
 history taking 156
- drugs, pharmaceutical
 causing male infertility 430
 empiric therapy 438
 erectile function 138–41
 exposure 236–40
 gonadotoxic 236–40
 history taking 156–57
 hormonal 237–38
 hypogonadotropic hypogonadism
 203
 intrauterine insemination side
 effects 497
- ductal obstruction
 congenital 393
 inflammatory 393
 operative techniques 395
 preoperative procedures 394
 reconstructive procedures 394
 traumatic 393
 vasectomy 393
 vasography 394
- ductuli efferentes, tight junctions
 280–81
- ductus epididymis 8–11
- dye exclusion assays 178
- dynein 54–55

- ectoplasmic specializations, Sertoli cells 52–53
- Edwards syndrome 644
- efferentiovasostomy 92, 93–94
- sperm maturation 94–95
- ejaculate
- absent 168
 - collection for semen analysis 159
 - composition 99–100
 - low volume 164–65, 168
 - pre-ejaculate 100
- ejaculation 142
- abnormalities 454–69
 - anatomic 456–57
 - functional 456
 - management 459–69
 - neuropathic 457–59
 - neurostimulatory management 460–64
 - pharmacologic 459
 - pharmacologic management 459–60
 - spinal cord injuries 465–69
 - surgical sperm retrieval 464–69
 - terminology 455–56
 - anatomy 142–43, 454–55
 - autonomic nervous system 143
 - central anatomy 144
 - central control 144
 - failure 164
 - hypogastric nerve 143, 455
 - neural control 455
 - neuroanatomy 143–44
 - neuropharmacology 145–46
 - pelvic nerve 143–44, 145, 455
 - peripheral control 143–44
 - physiological control 144–45, 454–55
 - reflex 454–55
 - somatic nervous system 145
 - spinal anatomy 144
 - spinal innervation 455
 - sympathetic nervous system 145
 - see also* premature ejaculation; retrograde ejaculation
- ejaculatory duct 99, 142
- anatomy 422, 422
 - balloon dilation 427
 - calcification 381, 425–26, 427
 - diameter 422, 423
 - distal inflammatory stenosis 380–81
 - embryology 421–22
 - excurrent system 392–94
 - physiology 422
 - stenosis 425–26, 427
 - stones 427
 - transurethral resection (TURED) 425–27
 - complications 426–27
 - success rate 426
- ejaculatory duct cysts
- TRUS 380, 426
 - TURED 387, 426
- ejaculatory duct obstruction 163, 165, 393–94, 421–27, 456–57
- acquired 422, 456–57
 - CBAVD differential diagnosis 423
 - chromotubation 424
 - complete 423, 456–57
 - congenital 393, 422, 456–57
 - diagnosis 422–24
 - etiology 422
 - evaluation 421, 422–24
 - functional causes 381
 - imaging 378–79, 423
 - management 425–27
 - MRI 424
 - partial 381–82, 423, 456
 - physical examination 423
 - semen analysis 423
 - seminal vesiculography 424
 - treatment 392
 - TRUS 423–24
 - TRUS-guided treatment 387–88
- elastase 314, 317
- electrocautery, needle 476
- electroejaculation 462–64
- physiological events 463–64
 - spinal cord injuries 463–64
- electromagnetic waves 240, 435
- electron spin resonance (ESR) 621
- embolization of varicocele 346–47
- angiographically guided 388–89
 - balloon 346, 347, 355
 - complications 355
- embryo(s)
- cryopreservation 529–30
 - failure to maintain 536
 - donated 520–21
- embryo transfer guidelines 502
- IVF 502
- live birth rates 366
- embryology of male genital tract 1–13
- embryonal cell carcinoma, imaging 384
- embryonic disc, trilaminar 3
- embryonic stem cells 649
- animal models 129
 - origins 128–29
 - primordial germ cell relationship 129–30
 - research 128–30
- emission 582
- emotional pain 517, 518
- medical team understanding 519
- emotional preparation for gamete donation 520
- empiric therapy 438–49
- androgens 445, 446–47
 - antiestrogen therapy 439–42
 - aromatase inhibitors 439, 442–43
 - bromocriptine 448
 - glutathione 448–49
 - GnRH 445–46
 - gonadotropins 443–45
 - indomethacin 447–48
 - kallikrein 447, 448
 - ketoprofen 447–48
 - medications 438
 - phosphodiesterase inhibitors 449
 - prostaglandins 447–48
 - testosterone rebound 447
 - vitamins 447, 449
 - zinc 449
- endocrine disorders
- diagnosis 202–09
 - evaluation 199
 - genetic 256–60
 - history taking 199–200
 - laboratory tests 200–02
 - physical examination 199–200
 - treatment 202–09
- endocrine disrupting chemicals (EDCs) 226, 227–28, 232–36
- additive effects 235
 - exposure risks 231–32
 - laboratory animal models 231, 232
 - methylation 647
 - steroid biosynthesis pathway 230–31
 - synergistic effects 235
- endocrine disruption hypothesis 227–28
- endothelins 141
- Endtz test 316–17, 623
- environmental estrogens (EEs) 226
- environmental factors 434–35
- enzyme immunoassays (EIA) 623–24
- enzyme-linked immunosorbent assay (ELISA) 604
- ephedrine sulfate 458
- epididymal contraception factors 486
- epididymal cysts, imaging 378, 383
- epididymal head, imaging 384
- epididymal lumen, fluid movement regulation 97
- epididymal proteins 96, 485

Index

- epididymal sperm retrieval 409–12, 584
 psychological issues 521
 semen processing 589
see also microsurgical epididymal sperm aspiration (MESA); percutaneous epididymal sperm aspiration (PESA)
- epididymal transit time for sperm 92
- epididymal tubule 392, 411
- epididymis 8–11, 91–92
 anastomosis to vas deferens 400
 development 90–91
 functions 393
 gene expression 96
 histology 91–92, 93
 hypoplastic 410
 male contraception role 486
 neurotransmitters 142
 obstruction 163, 400
 imaging 377
 pain post-vasectomy 478
 physical examination 157–58
 sperm
 concentration 97
 retrieval 409–12
 storage 91, 97–98
 transport 96–97
- epididymitis 155–56, 297
- epididymo-orchitis, *Chlamydia trachomatis* 431
- epididymovasostomy *see* vasoepididymostomy
- epigenetics 647
- epilepsy 157
- eppin 485
- Epstein–Barr virus (EBV) 303, 305
- erectile dysfunction 162, 454
 diabetes mellitus 458
 multiple sclerosis 458
- erectile function 133
- erection 132–38
 autonomic nervous system 134
 central control 134
 hemodynamics 133–34
 intracavernosal pressure 133–34
 local control 135, 136–38
 neurological control 134–38
 neurotransmitters 133, 134, 135
 nocturnal 134
 peripheral control 134–36
 pharmaceutical drugs 138–41
 reflexogenic 134
 second messengers 137
 smooth muscle
 relaxation 137–38
 tone 138
- ERM (Ets-related molecule) 78
- erythropoiesis, testosterone replacement therapy effects 209
- Escherichia coli* 302–03
- epididymitis 297
- estradiol
 GnRH neuron burst firing 18
 gonadotropin secretion 20–21
 measurement 201
- estrogens 439
 disruption by DDT 234
 endocrine disruption hypothesis 227–28
 environmental 226
 GnRH secretion regulation 18
 hypothalamic–pituitary–gonadal axis requirement 439
- ethylene dibromide 233
- etonogestrel 482
- excretory ducts 6
- excretory organs, development 4
- experimental allergic orchitis model 285
- expressed sequence tags (ESTs), sperm 128
- expression microarrays 648
- external genitalia development 11–13
- extratesticular ductal system syndromes 262–64
- FA-1 sperm receptor 110
 antibodies against 284
- fallopian tubes, female infertility 369–70
- FATE gene mutations 122–23
- fecundability 364
- female factors 162, 363
 age 365–66
 chromosome abnormalities 366
 fecundability 364
- female infertility 362–73
 age factors 365–66, 371
 causes 362–63
 cervical factors 369
 chromosome abnormalities 366, 367
 diagnostic evaluation 362, 363
 follicle number decline 372
 gonadotropins 366–67, 368
 history 363–64
 history taking 364
 luteal phase deficiency 368–69
 male partner age 366
 ovarian reserve assessment 371–72
 ovulatory cycles 367–68
 ovulatory factors 366–69
 peritoneal factors 370–71
 physical examination 364
- prevalence 363
 prognosis 365–66
 tubal factors 369–70
 uterine factors 370
- female pseudohermaphroditism 260
- Ferti Care vibrator 461
- fertility data analysis 541–48
 diagnostic tests 544–46
 outcome studies 546–48
 statistics 541–46
- fertility failure, acrosin-related 112
- fertility markers, P34H 110
- fertility preservation
 legal issues 528–39
 minor male patients 532–33
 model legislation 537–38
 posthumous reproduction 533–35
 provider liability 535–37
 surviving relatives 536
see also cryopreservation; informed consent; sperm cryopreservation
- fertilization 104
 failure 104
 sperm capacitation 104–07
 sperm–egg interactions 108–14
- fertilization antigen 1 (FA-1) 282, 484–85
- fertilization-promoting peptide (FPP) 106
- FGFR1* gene mutations 265
- fibrin glue 398
- finasteride 237
- fine-needle aspiration mapping of spermatogenesis 217
- fish consumption, PCB exposure 235–36
- flow cytometry
 leukocytes 317
 ROS analysis 621
 semen white blood cell assay 614
 sperm chromatin structural assay 633–35
 testicular biopsy analysis 220
- fluorescence in-situ hybridization (FISH) 188–91, 643
 chromosome abnormalities 644
 chromosome structural reorganization carriers 190
 clinical utility 190
 preimplantation genetic diagnosis 509
 sex chromosome numerical abnormalities 189–90
 technique 188
 testicular biopsy 220
- fluorescence spectroscopy 624

- follicle number decline 372
- follicle-stimulating hormone (FSH)
14, 439, 480
- clomiphene citrate effects 440
- defects in hypogonadotropic
hypogonadism 266
- empiric therapy 444
- exogenous 444
- feedback regulation 20–21
- feed-forward regulation 19–20
- female infertility 366–67, 368
- functions 19
- GnRH secretion 18
- inhibin B production 23–24
- measurement 169–70, 200–01, 201–02
- azoospermia 162–63
- ovarian reserve 371–72
- recombinant human 443
- reproductive axis physiology 199
- secretion patterns 22
- spermatogenesis 19
- control 59, 82
- target antigen 484
- testosterone secretion 19
- varicocele 333–34, 341
- follicle-stimulating hormone (FSH)
knockout mice 59–60, 82
- follicle-stimulating hormone receptor
(FSHR) defects 266
- follicle-stimulating hormone receptor
knockout mice (FORKO)
60–61, 82
- follicular fluid, acrosomal exocytosis
111
- free radical(s)
aging 39
- Leydig cells 39–40
- free radical scavengers, sperm
cryopreservation 594
- frequency histogram 546
- fructose, seminal vesicle secretions 100
- functional syncytium 137
- G proteins 136–37
- gamete(s)
cryopreservation 529–30
- failure to maintain 536
- function 484
- fusion 112–13
- production 484
- gamete donation
confidentiality 522
- donors 523
- anonymous 521–22
- identification 525
- identified 521–22
- known 521–22
- litigation 530
- privacy 522
- psychological issues 520–21, 521–22
- disclosure/nondisclosure 523–24,
524–25
- medical team recommendations
523
- religious factors 524
- secrecy 522
- social factors 524
- gamete intrafallopian transfer (GIFT)
503
- gamete micromanipulation
techniques 500, 503–07
- Gaussian distribution 542–43, 547
- gene expression modulation 647
- gene imprinting 647
- gene mutations 646
- animal models 646
- human males 646–47
- genetic anomalies, oligospermia 494
- genetic anticipation 259
- genetic diagnosis 642–43
- genetic factors
azoospermia 251–56
- endocrine defects 256–60
- extratesticular ductal system
syndromes 262–64
- hypogonadotropic hypogonadism
265–66
- hypothalamic–pituitary–gonadal
axis defects 264–66
- oligospermia 251–56
- sexual development disorders
260–62
- spermatozoa function disorders
266–67
- see also* chromosome abnormalities/
anomalies
- genetic signatures, testis biopsies 128
- genetic testing
nonobstructive azoospermia
162–63
- obstructive azoospermia 163
- genital ducts, embryology 8–11
- genital tract
female 104–08
- male 98
- obstruction and antisperm
antibodies 283
- genitalia
external 11–13
- male/female differentiation 91
- partial androgen insensitivity 258
- germ cell(s)
abnormal apoptosis 185
- differentiation stages 129
- embryonic stem cell relationship
129–30
- hypoplasia 218
- loss by apoptosis 227
- origins 128–29
- pluripotency 129–30
- germ cell nuclear factor (GCNF) 80–81
- germ cell tumors
malignant 383
- testicular microlithiasis 386
- germ layers 1
- germinal cell aplasia 218, 219
- Gianturco coils 346
- glands of Littre 100
- glial-derived neurotrophic factor
(GDNF) 78
- globozoospermia 179, 266
- glutamine polymorphisms, androgen
receptors 259
- glutathione 448–49
- oxidized 623, 625
- reduced 623
- glutathione peroxidase 625
- glycerol 595
- GNRHR* gene defect 265
- Golgi apparatus, acrosome
formation 80
- gonadal agenesis 260
- gonadal development 8, 10
- intersex 260–61
- gonadal dysgenesis 260
- mixed 261
- gonadal harvesting, minor male
patients 533
- gonadal ridge 8
- primordial germ cells 76
- gonadotoxicants *see* chemical exposure
- gonadotropin(s) 14, 19–22, 443–45
- aromatase blockade 20
- defects in hypogonadotropic
hypogonadism 266
- exogenous 443, 445
- feedback regulation 20–21
- feed-forward regulation 19–20
- female infertility 366–67, 368
- functions 19
- secretion patterns 21–22
- secretion regulation 19–22
- spermatogenesis control 59
- testosterone secretion 19
- see also* follicle-stimulating
hormone (FSH); luteinizing
hormone (LH)
- gonadotropin-releasing hormone
(GnRH) 14–19, 439, 480
- autocrine regulation 14–16
- empiric therapy 445–46

Index

- gonadotropin-releasing hormone (GnRH) *cont.*
 endocrine regulation 17–18
 gamete production 484
 gonadotropin secretion regulation 19–20
 hypogonadotropic hypogonadism therapy 204–05
 Kallmann syndrome 265
 neuron coordination 14–16
 paracrine regulation 16–17
 production 439
 pulsatile secretion 18
 release regulation 15
 reproductive axis physiology 199
 secretion
 pattern 18–19
 regulation 14
 spermatogenesis regulation 82
 synthetic analogs 443–44
 therapeutic 443–44
 varicocele 333–34
 adolescent 341
- gonadotropin-releasing hormone (GnRH) analogs 480, 483
 gonadotropin-releasing hormone (GnRH) antagonists 500
 gonadotropin-releasing hormone (GnRH) neurons 16, 17, 18–19
 gonadotropin-releasing hormone II (GnRH-II) 16–17
 gossypol 486
GPR54 gene defect 265–66
 Gram-negative infections 302–03
 granulocyte elastase 314, 315, 317
 tests 614
 granulocytes 311
 peroxidase-positive 614
 ROS effects 311–12
 GREAT gene 262
 GREAT receptor 262
 Griess reaction 624
 grieving 520–21
 growth hormone (GH) 24–25
 guanosine diphosphate (GDP) 35
 guanosine monophosphate, cyclic (cGMP) 137
 guanosine triphosphate (GTP) 35
 guanylate cyclase activators 141
 gubernaculum 11
 guilt feelings 517, 518
 gynecomastia 157
 testosterone replacement therapy 208
- HaloSperm kit 637
 head injury, ejaculation abnormalities 458–59
- heat, contraceptive function 486
 heat shock proteins,
 leukocytospermia 316
 heavy metals, testicular cell death/necrosis 227
 hemacytometer 553, 585
 hematoma, vasectomy
 complications 478
 hemizona assay 113, 171, 182–83
 hemizona index 502–03
 hemoclips 476
 hepatitis B, donor semen screening 597–98
 hepatitis C, donor semen screening 597–98
 HEPES buffer 585, 595
 hermaphroditism, true 260
 hernia uteri inguinale 8
 herpes simplex virus (HSV) 303–05
 heterologous gamete assay 113–14
 highly active antiretroviral therapy (HAART) 307
 highly DNA sustainable cells (HDS) 634–35, 636
 hip flexor response, spinal cord injuries 461–62
 history taking 154–55, 155–58
 cancer 156
 childhood illnesses 155
 endocrine disorders 199–200
 illicit drugs 156
 lifestyle exposures 157
 medication use 156–57
 occupational exposures 157
 reproductive history 154–55
 surgical history 156
 systemic disease 155–56
 HIV infection 304, 305–07, 431–32
 donor semen screening 597–98
 leukocytospermia 432
 spermatozoa changes 432
 treatment 304, 305–07
 Hodgkin disease, sperm collection for future insemination 598–99
 homologous recombination 78–79
 hormonal male contraception 480–84
 hormonal tests 169–70
 hormone(s)
 endocrine disruption hypothesis 227–28
 exposure timing 227
 imbalance 227–28
 immune regulation 281
 reproductive axis physiology 199
see also endocrine disorders;
 endocrine disrupting chemicals (EDCs); *named hormones*
- hormone therapy
 adjuvant for varicocele 354
 medications 237–38
 Hox genes 90–91
 HSP60 316
 human chorionic gonadotropin (hCG) 8, 237
 adjuvant therapy 444
 following varicocelectomy 354
 empiric therapy 444
 exogenous 443
 hypogonadotropic hypogonadism therapy 203–04
 idiopathic oligospermia treatment 444–45
 Kallmann syndrome 432–33
 spermatogenesis recovery 237–38
 TGF effects 24
 human follicle-stimulating hormone (hFSH), target antigen 484
 human herpes virus 303
 human immunodeficiency virus (HIV) *see* HIV infection
 human menopausal gonadotropin (hMG) 237–38, 432–33
 empiric therapy 444
 exogenous 443
 idiopathic oligospermia treatment 444–45
 human papillomavirus (HPV) 305
 human tubal fluid (HTF) medium 585, 595
 humoral immunity 277, 279
 hyaluronidase 180
 hydrocele 200
 imaging 383
 hydrogen peroxide 183
 hydroxyl radical 183
 5-hydroxytryptamine (5-HT) *see* serotonin
 hypergonadotropic hypogonadism 205–06
 androgen resistance 205–06
 defective androgen synthesis/response 205–06
 diagnosis 205
 5 α -reductase deficiency 205
 treatment 205–06
 hyperprolactinemia 433
 hyperthermia, varicocele 335
 hypogastric nerve 142–43
 ejaculation 143, 455
 hypogastric plexus
 damage 457–58
 ejaculation 143

- hypogonadism 200
 azoospermia 163
 combined primary and secondary 206–09
 primary 205–06
 secondary 202–05
 testicular biopsy 223
- hypogonadotropic hypogonadism 202–05
 acquired 202–03
 clomiphene citrate therapy 432, 442
 convertase 1
Dax1 gene defect 265
 diagnosis 202–03
 evaluation 204
 genetic factors 265–66
GnRHR gene defect 265
 gonadotropin defects 266
 gonadotropin treatment 443
GPR54 gene defect 265–66
 idiopathic 202, 265
 kisspeptin gene defect 265–66
NELF gene defect 265
PC1 gene defect 266
 Prader–Willi syndrome 266
 treatment 203–05
see also Kallmann syndrome
- hypo-osmotic swelling test (HOST) 178, 505
- hypospadias 260, 261
 genes 261
 steroid receptor pathway defects 261
- hypospermatogenesis 218
- hypothalamic–pituitary–gonadal axis 14–25, 439, 480
 corticotropin-releasing hormone 24
 defects 264–66
 feedback regulation 15, 20–21
 feed-forward regulation 15, 19–20
 functional unit 200
 genetic factors 264–66
 gonadotropins 14, 19–22
 growth hormone 24–25
 IGF-1 24
 IL-10 24
 inhibin B 23–24
 laboratory assessment 200–02
 spermatogenesis 59, 60
 regulation 82
 steroid requirements 439
 testicular factors 22–25
 testosterone 22–23
 TGF 24
 varicocele 334
- hypothalamus, erectile function 134
- hypothetical decision space 548
- hypoxia, varicocele 334–35
- hypoxia-inducing factor 1 α (HIF-1 α) 334
- hysterosalpingogram 369–70
- hysteroscopy 370
- Id proteins 57–58
- imaging 375–89
 congenital absence of vas deferens 377–78
 cryptorchidism 382, 383
 ejaculatory duct obstruction 378–79, 423
 epididymal cysts 378
 epididymal head 384
 epididymal obstruction 377
 hydrocele 383
 median cysts 379–80
 pituitary adenoma 387
 renal disorders 387
 scrotal masses 382–85
 spermatocele 383, 384
 testicular microlithiasis 385–86
 treatment guidance 387–89
 varicocele 375–77, 376–78, 378–79
see also named modalities
- immune activation 282–84
- immune cells in semen 307–11
- immune infertility mechanisms 282–85
- immune system
 architecture 278
 normal function 277
 self antigen tolerance 280
 testes 279–82
- immunity 277
 mucosal 279, 281
 regional 279
 systemic 281
see also cell-mediated immunity;
 humoral immunity
- immunobead test (IBT) 285, 604–05, 610
 advantages 608
 clinical significance 607
 data interpretation 606
 detailed assay 606
 direct method 604–05, 606
 indirect method 605, 606
 lab results 606–07
 limitations 608
 procedures 605–06
 quality control management 608–10
 sperm binding 605
 variability 608–09
- immunocontraceptives 483–85
- immunoglobulin(s) 279
 immunobead test 604–05, 607
- immunoglobulin A (IgA) 279
 against sperm 283–84
- immunoglobulin G (IgG) 283–84
- immunoglobulin M (IgM) 283–84
- immunohistology
 leukocytospermia 317
 semen white blood cell assay 614, 615
- immunologic infertility 603
 diagnosis 285–86
 treatment 286
see also antisperm antibodies
- immunologic techniques in leukocytospermia 317
- immunologic tolerance 281–82
- immunosuppression 281
 systemic for immunologic infertility 286
- implantation 1
- in-situ nick translation 633
see also TUNEL assay
- in-vitro assays for sperm–egg interactions 113–14
- in-vitro fertilization (IVF) 29, 500–03
 birth defects 507–08
 controlled ovarian hyperstimulation 500
 cryopreserved sperm 599
 DNA damage 185–87
 embryo transfer 502
 fertilization rate 502–03
 fresh sperm 599
 hypergonadotropic hypogonadism 205
 immunologic infertility treatment 288
 male-factor outcomes 502–03
 oocyte classification 500
 oocyte preparation 500
 psychological issues 519–20
 medical team recommendations 522
 semen processing 589
 sperm
 fertility 94
 morphology 577
 preparation techniques 501–02
 sperm banking for azoospermia 599–600
 spinal cord injuries 468–69
 success rate 506
see also sperm retrieval
- indirect immunofluorescence assay 604
- indomethacin 447–48
- infections 295–307, 431–32
 acute 295

Index

- infections *cont.*
 bacterial 297–303
 diagnostic criteria 295
 ejaculatory duct obstruction 393
 Gram-negative 302–03
 sites 295–97
 subclinical 295
 testing for sperm retrieval 407
 vasectomy complications 478
 viral 303–07
- infertility
 definition 500
 etiology 642–45
 experience 517
 grieving for 520–21
 idiopathic 438, 444
 molecular defects 645–47
 psychological reactions 516–18
 unexplained 162, 187
see also female infertility;
 immunologic infertility
- inflammation 295
see also leukocytospermia
- inflammation mediators 307–16
- information, internet resources 435
- informed consent 528–30
 documentation 529, 536–37
 minor male patients 532–33
 posthumous reproduction 535, 536–37
 withdrawal 538
- inguinal hernia, childhood repair 398
- inhibin B 23–24, 480
 gonadotropin secretion 21
 ovarian reserve measurement 371
- inhibins 199
 gonadotropin secretion 21
 spermatogenesis regulation 82
- insidomine, intracavernosal
 injection 141
- insulin-like 3 hormone (INSL3) 261–62
- insulin-like growth factor 1 (IGF-1)
 GnRH secretion regulation 17
 hypothalamic–pituitary–gonadal
 axis 24
 testosterone secretion 19
- insurance providers, cancer
 treatments 537
- insurance services, provider liability
 535–37
- intact ZP assay 113
- integrins, sperm–egg fusion 113
- intentionality, posthumous
 reproduction 535
- intercourse frequency 154
- interferon gamma (IFN- γ) 285
- interleukin 1 (IL-1), spermatogenesis
 regulation 61–62
- interleukin 2 (IL-2) 315
- interleukin 4 (IL-4) 315
- interleukin 6 (IL-6) 315
 spermatogenesis regulation 62
- interleukin 8 (IL-8) 315
- interleukin 10 (IL-10) 315
 hypothalamic–pituitary–gonadal
 axis 24
- interleukin 12 (IL-12) 315
- intermediate filaments, Sertoli cells
 53–54
- internet resources 435
- intersex 260–61
 gonadal development 260–61
- intracavernosal injection
 insidomine 141
 nitroprusside 141
 papaverine 139
 phentolamine 140
 prostaglandin E₁ 139
 vasoactive intestinal peptide 140
- intracavernosal pressure 133–34
- intracellular ion concentrations,
 sperm capacitance 106, 107
- intracytoplasmic sperm injection
 (ICSI) 29, 177, 500, 503, 504
 age factors 504–05
 antisperm antibodies 610
 birth defects 507–08
 costs 509
 cryopreserved sperm 599
 DNA damage tests 187
 DNA fragmentation 633
 fresh sperm 599
 hypergonadotropic hypogonadism
 205
 immunologic infertility 288
 indications 504, 505
 outcome 504
 psychological issues 519–20
 medical team recommendations
 522
 semen processing 589
 sex-chromosome anomalies 188
 sperm banking for azoospermia
 599–600
 sperm factors 505–07
 sperm fertility 94
 sperm morphology 577
 sperm morphology 577
 spinal cord injuries 468–69
 success rate 506
 technique 504
see also sperm retrieval
- intratubular germ cell neoplasia
 (ITGCN) 219–20
- intrauterine insemination (IUI) 493–98
 age factors 495–96
- azoospermia 496
 chain of custody 497
 complications 496–97
 costs 495
 counseling 495
 donor 494
 female screening tests 494
 genetic screening 495
 immunologic infertility treatment
 287
 indications 493–95
 insurance issues 495
 laboratory errors 497
 medication side effects 497
 ovulation inducers 495–96
 pregnancy complications 497
 prescreening 494
 procedure 495
 sperm
 abnormal morphology 496
 morphology 577
 processing 584
 testing 494
 sperm donor lab test panel 495
 spinal cord injuries 467–68
 success rates 495–96
 technique 493–95
 varicocele 496
- intravaginal ejaculatory latency time
 (IELT) 456
- intravaginal insemination, spinal cord
 injuries 466–67
- intra-vas device 476
- IRAG (IP₃-receptor-associated
 G-kinase substrate) 137
- ischiocavernosus muscles 132, 143
- isoflavones 449
- isoprostane method 623
- IZUMO protein 112–13
- Johnsen scoring system for testicular
 biopsy 221
- Jsd* retrogene 124
- junction adhesion molecules (JAMs) 56
- KAL1* gene 265
- kallikrein 447, 448
- Kallmann syndrome 202
 hypogonadotropic hypogonadism 265
 inheritance 432
 spermatogenesis 432–33
 treatment 432–33
- Kartagener syndrome 155–56, 157,
 179, 267
- karyotype analysis 643–44
 nonobstructive azoospermia
 162–63

- K_{ATP} channels 137
 kelch gene, human homolog 648
 Kennedy syndrome 259, 508
 keratins 53
 ketoprofen 447–48
 kidneys, embryology 2, 90
 kinesin 54–55
 kisspeptin
 gene defect 265–66
 GnRH secretion regulation 17
hKLHL10 mutations 648
 Klinefelter syndrome 189–90, 205, 251–52, 644
 assisted reproduction 508
 clinical spectrum 252
 sperm retrieval 416
 TESE 252
 treatment 443
 laboratory testing of subfertile male
 additional tests 168–71
 endocrine evaluation 200–02
 initial 158–61
 lactate dehydrogenase C_4 (LDH- C_4) 485
 laser capture microdissection 648
 legal issues 528–39
 donor insemination 531–32
 gamete cryopreservation 529–30
 medical liability 537
 minor male patients 532–33
 model legislation 537–38
 posthumous reproduction 533–35
 procreative decisions 530
 provider liability 535–37
 sperm cryopreservation 528–29
 surviving relatives 536
 see also informed consent
 leukemia 156
 imaging 384
 leukemic inhibitory factor (LIF) 62
 leukocytes 307–11, 554
 chemiluminescence contamination 620
 counts 316
 flow cytometry 317
 immunohistology 317
 migration assay 286
 NO production 314
 ROS
 effects 311–12, 313, 314
 generation 618
 semen analysis 310–11, 552–53, 613–15
 semen levels 170–71
 subpopulations 308–10
 see also semen; white blood cell assay
 leukocytospermia 307–21
 cellular immunity 285
 clinical relevance 311
 definition 316
 detection 316–17
 histology 316–17
 HIV infection 432
 IL-2 315
 IL-8 315
 immunological techniques 317
 morphology 316–17
 prevalence 308
 prostatitis 321
 semen analysis 553
 spinal cord injury 320–21, 466
 treatment 317–20
 levator ani muscles 143
 levonorgestrel 482
 Leydig cell(s) 8, 29
 adult 31–32
 steroidogenic function 34–38
 testosterone production 32, 34–38
 aging 38–40
 androstenedione production 34–35
 development 29–34
 failure 200
 fetal 29–31
 free radicals 39–40
 IGF-1 effects 24
 immature 32
 inhibin B 23
 LH effects 32
 progenitor 29, 31, 650–51
 progesterone production 34–35
 reactive oxygen species 39–40
 redox environment 39–40
 stem 32–34, 378–79, 650–51
 aging 34
 testosterone secretion 19
 Leydig cell tumor 384, 385
 life crisis 516–17
 chronicity 517
 lifestyle exposures 157
 chemicals 229–30
 gonadotoxic 240–41
 limbic system, erectile function 134
 linear models 547
 lipid peroxidation measurement 623
 lipids, testosterone replacement
 therapy effects 209
 liquid nitrogen 596–97
 litigation
 donor gametes 530
 sperm cryopreservation 529
 liver, testosterone replacement therapy
 hepatotoxicity 209
 logistic regression 547
 lonidamine 486
 loss feelings 517
 lubricants 154–55
 lucigenin 620
 lumbar spinothalamic cells 144
 lumbar sympathetic ganglia 455
 damage 457–58
 luminol 619–20
 luminometers 620
 luteal phase deficiency 368–69
 luteinizing hormone (LH) 14, 439, 480
 aging effects 38–39
 clomiphene citrate effects 440
 defects in hypogonadotropic
 hypogonadism 266
 feedback regulation 20–21
 feed-forward regulation 19–20
 female infertility 366–67, 368
 functions 19
 GnRH secretion 18
 IGF-1 effects 24
 isolated deficiency 202
 Leydig cell effects 32
 measurement 200–01, 201–02
 reproductive axis physiology 199
 secretion patterns 21
 serum levels 22
 spermatogenesis 19
 control 59, 82
 steroidogenesis 35
 surge 367
 testosterone
 plasma levels 22–23
 secretion 19
 TGF effects 24
 luteinizing hormone (LH) knockout
 mice 61, 82–83
 luteinizing hormone receptor (LHR)
 defects 266
 luteinizing hormone receptor
 knockout mice (LHRKO) 61, 82–83
 luteinizing hormone-releasing
 hormone (LH-RH) 237
 lymphocytes
 activated 279
 semen 307–08
 lymphoma 156
 imaging 384
 sperm collection for future
 insemination 598–99
 M42 antigen 484–85
 macroadenoma 433

Index

- magnetic resonance imaging (MRI)
 cryptorchidism 382, 383
 ejaculatory duct
 distal inflammatory stenosis 380
 obstruction 424
 partial obstruction 381–82
 median cysts 380
 pituitary adenoma 387
 seminal vesicle 376
 major histocompatibility complex (MHC) 277–78
 Makler counting chamber 553–54
 male pseudohermaphroditism 260
 male-specific Y (MSY) 253–54
 malignancy
 detection by imaging 385
 testicular biopsy 219–20, 222
 marijuana use 156
 causing male infertility 430
 gonadotoxicity 241
 marriage dissolution, model
 legislation 538
 matrix metalloproteases (MMPs),
 Sertoli cell secretion 65
 maturation arrest 218, 219
 chromosomal recombination
 defects 125–26
 maxi-K channels 137
 media
 human tubal fluid 585, 595
 protein source 585
 semen processing 585, 586
 sperm cryopreservation 595–96
 medial amygdaloid nucleus 144
 medial preoptic area 134, 144
 median cysts
 imaging 379–80
 semen-containing 379
 medical liability 537
 medical team
 consultation with both partners 519
 psychological issues
 emotional factors 519
 gamete donation disclosure/
 nondisclosure 525
 recommendations 519, 522–23
 understanding 519
 successful treatment definition 519
 Medicated Urethral System for
 Erection (MUSE™) 139–40
 medications *see* drugs, pharmaceutical
 medroxyprogesterone acetate
 (MPA) 482
 mega seminal vesicles 381
 meiosis 78–79
 anaphase 79
 desynapsis 79
 diplotene stage 79
 metaphase 79
 pachytene stage 78–79
 prophase I 78–79, 125
 telophase 79
 meiotic arrest 124
 meiotic drive 123
 melanocortin agonists 140
 melanotan II (MT-II) 140
 mesoderm 1, 4
 mesodermal ridge 90
 mesonephric ducts 2, 7, 90–91
 differentiation failure in CBAVD
 262, 264
 mesonephros 1, 90
 messenger RNA 128
 GnRH secretion 18
 mesterolone 446
 metabolomic profiling 628
 metanephros 2, 90
 methyl bromide 232, 233
 methyl chloride 232–33
 7 α -methyl-19-nortestosterone
 (MENT) 481
 methylation 647
 endocrine disruption 647
 methylxanthines 449
 microadenoma 433
 microdissection testicular sperm
 extraction (micro-TESE) 389,
 407, 413–14, 416
 microepididymal sperm retrieval,
 psychological issues 521
 microRNA 647–48
 microsurgical epididymal sperm
 aspiration (MESA) 410–12, 584
 mini-MESA 411–12
 obliterative 411
 sperm cryopreservation 595
 microsurgical reconstruction 392–403
 assisted reproductive technologies
 403
 complex vasal 398–99
 history taking 394
 obstructive interval vs outcome 400
 operative techniques 395
 physical examination 394
 preoperative procedures 394
 procedures 394
 testicular blood supply 403
 vas deferens 395
 vasal length 402
 vasoepididymostomy 394–95, 400–02
 vasovasostomy 394–95, 395–400
 microtubule organizing center
 (MOC) 54
 microtubules, Sertoli cells 54–55
 minimal androgen insensitivity
 syndrome (MAIS) 258–59
 mini-microsurgical epididymal sperm
 aspiration (mini-MESA)
 411–12
 minor male patients, legal issues
 532–33
 mitosis, spermatogonia 78
 MIWI RNA 647–48
 mixed agglutination reaction 285,
 604, 605
 MLH1 protein 124–25, 127
 antibodies 125
 focus frequency heterogeneity
 126–27
 MLH3 protein 127
 molecular defects 645–47
 morula 1
 moxisylyte 140
 MSH4 protein 127
 mucosal immunity 279, 281
 Müllerian ducts 8, 90, 421–22
 cysts 422, 424, 425
 persistent Müllerian duct syndrome
 264
 regression 90
 Müllerian-inhibiting substance *see*
 anti-Müllerian hormone
 (AMH)
 multiple sclerosis 155–56
 ejaculation abnormalities 458
 multivariates 547
 mumps orchitis 155
 mycoplasma 298–302
 detection 302
 investigations 300, 301
 pyospermia 167–68
 urethritis 295
Mycoplasma genitalium 167–68
Mycoplasma hominis 298
 myelodysplasia, ejaculation
 abnormalities 458
 myeloperoxidase test *see* Endtz test
 myosin light chain kinase (MLCK) 136
 myotonic dystrophy 155–56
 Nagler maneuver, varicocele 336
 nasal embryonic LHRH factor gene
 (NELF), defect 265
 natural killer (NK) cells 278
 near-red confocal imaging 223
 needle electrocautery 476
Neisseria gonorrhoeae 295, 297
 donor semen screening 597–98
 epididymitis 297
 NELF gene defect 265
 nephrons 2

- nestin 53
 nestorone gel 483
 neuropeptide Y
 ejaculation 145
 vas deferens innervation 142
 neurotransmitters
 epididymis 142
 erectile function 133, 134, 135, 137
 nicotinamide adenine dinucleotide (NADH) 619
 nicotinamide adenine dinucleotide phosphate (NADPH) 619
 nicotine exposure 230
 nifedipine, autonomic dysreflexia 460
 nitric oxide (NO)
 erectogenic 133, 137
 leukocyte production 314
 vas deferens innervation 142
 nitric oxide (NO) donors 141
 nitric oxide synthase (NOS) 137
 nitro blue tetrazolium (NBT) test 620
 nitrogen, liquid 596–97
 nitroimidazole derivatives 486
 nitrones 621
 nitroprusside, intracavernosal injection 141
 nitroso compounds 621
 nonlinear models 547–48
 non-Mendelian gene modifiers 647
 noradrenaline, erectile function 136
 norethisterone 483
 nucleus paragigantocellularis 134, 144
 null hypothesis 543
 nutcracker phenomenon 332

 obesity, chemical exposure 229
 occludins 56
 occupational history 157
 oligoasthenospermia, GnRH therapy 446
 oligoasthenoteratozoospermia (OAT) 163–64
 genetic defects 507, 508
 meiotic disturbance 190
 sperm preparation techniques for IVF 502
 oligospermia
 algorithm 169
 DBCP exposure 233–34
 epididymal obstruction 377
 genetic anomalies 494
 genetic factors 251–56
 GnRH therapy 445–46
 idiopathic 444–45
 intrauterine insemination use 494, 496
 semen processing 589

 sperm chromosome anomalies 188
 sperm transport failure 583
 testicular biopsy 222
 oocytes
 classification 500
 cryopreservation 529–30
 donated 520–21, 523–24
 litigation 530
 homologous 113–14
 insemination for IVF 502
 preparation 500
 ICSI 504
 sperm penetration interference 284
 oolemma
 sperm fusion 112–13
 sperm penetration 582–83
 opiates, gonadotoxicity 241
 opsonization, sperm 284
 optical coherence tomography 223
 orchidometer 200
 orchiectomy, partial 222
 orchitis 297
 antisperm antibodies 283
 orgasm 142
 orgasmic dysfunction, multiple sclerosis 458
 outcome studies 546–48
 dichotomous test 544
 outer dense fibers (ODF) 81
 ovarian cancer, fertility drug association 497
 ovarian hyperstimulation, controlled 500
 ovarian hyperstimulation syndrome 497
 risk with ART 507
 ovarian reserve assessment 371–72
 ovaries, development 10
 ovulation
 female infertility 366–69
 follicular phase 367
 LH surge 367
 luteal phase deficiency 368–69
 screening for dysfunction 367–68
 ovulation inducers, intrauterine insemination 495–96
 ovum donation, psychological issues 523–24
 oxidative phosphorylation, disruption 227
 oxidative stress 183, 311–14
 aging 39
 semen 618, 623
 biomarkers 628
 measurement 619
 spermatozoa 183
 varicocele 334–35

 P34H sperm receptor 110
 P95 protein 485
 pampiniform plexus, varicocele 331, 332–33
 PAP7 protein 37
 Papanicolaou stain 613
 papaverine, intracavernosal injection 139
 paramesonephric ducts 2, 7–8
 parasympathetic nuclei, pro-erectile sacral 134
 paraventricular nucleus, erectile function 134, 144
 paravertebral sympathetic ganglia 458
 parenthood 516
 partial androgen insensitivity (PAIS) 258
 partial zona dissection (PZD) 500, 503, 504
 assisted hatching 509
 Patau syndrome 644
 paternity, donor insemination 532
PC1 gene defect 266
 pelvic floor muscles 143
 pelvic nerve 142–43
 ejaculation 143–44, 145, 455
 pelvic splanchnic nerve 457
 pelvic surgery, ejaculation abnormalities 457–58
 penile vibratory stimulation (PVS) 460–62
 physiological events 463–64
 spinal cord injuries 460, 461–62, 463–64
 penis
 anatomy 132–33
 arterial blood supply 132, 133
 development 8, 11–13
 intracavernosal sinusoids 133
 neurovascular bundle 132
 physical examination 157–58
 smooth muscle cells 133
 gap junctions 137
 smooth muscle tone 133
 veno-occlusive mechanism 133
 venous drainage 132–33
 see also detumescence; erectile dysfunction; erection; tumescence
 pentoxifylline 449
 percutaneous epididymal sperm aspiration (PESA) 412
 CBAVD 415
 sperm cryopreservation 595
 perinephros 1

Index

- peripheral-type benzodiazepine receptor (PBR) *see* TSPO translocator protein
- peritoneum, female infertility 370–71
- peritubular myoid cell secreted mesenchymal factors (PModS) 57
- periurethral muscle activity 454–55
- peroxidase test 316–17, 613
- protocol 615
- persistent Müllerian duct syndrome 264
- pesticides 434–35
- antiandrogens 228
- phallus
- development 11–13
- see also* penis
- phenotypic sex development 11–13
- phenoxybenzamine 140
- phentolamine, intracavernosal injection 140
- phenylpropanolamine 458
- phosphodiesterase 137
- phosphodiesterase type 5 (PDE-5) inhibitors 138–39
- empiric therapy 449
- gonadotoxicity 240
- phthalates 236
- physical examination of subfertile male 157–58
- endocrine disorders 199–200
- pituitary adenoma, imaging 386, 387
- pituitary gland
- infiltrative diseases 203
- see also* hypothalamic–pituitary–gonadal axis
- PIWI RNA 647–48
- polychlorinated biphenyls (PCB) exposure 232, 235–36
- mechanisms of action 236
- polycystic kidney disease 381
- polyhalogenated aromatic hydrocarbons 234–36
- polymerase chain reaction (PCR) 643
- polymorphonuclear neutrophils (PMNs)
- ROS generation 618
- semen analysis 552–53
- polyvinyl chloride (PVC) 236
- polyspermia block 113
- postcoital test (PCT)
- semen analysis 160
- sperm–cervical mucus interaction 171, 179–80
- posthumous reproduction
- informed consent 535, 536–37
- intentionality 535
- legal issues 533–35
- model legislation 537
- sperm cryopreservation 533–35
- potassium channels 137
- Potter syndrome 264
- powerlessness feelings 519
- Prader–Willi syndrome, hypogonadotropic hypogonadism 266
- predictive values 544
- preganglionic sympathetic neurons, ejaculation 143
- pregnancy
- chemical 364
- complications with intrauterine insemination 497
- DNA damage tests for recurrent loss 187
- multifetal 497
- risk with ART 507
- occult 364
- rate 153
- DNA damage 185
- see also* abortion, spontaneous
- preimplantation genetic diagnosis (PGD) 509–10
- preimplantation genetic screening (PGS) 510
- premature ejaculation 455–56
- SSRI therapy 146, 456, 459
- treatment 456
- preoptic area, medial 134, 144
- prepuce development 13
- primary ciliary dyskinesia 155–56, 179
- genetic factors 267
- primitive streak 1
- primordial germ cells 128–29
- embryonic stem cell relationship 129–30
- privacy, gamete donation 522
- proacrosin 112
- probability 541–42
- P*-value pitfalls 543–44
- processus vaginalis 11
- procreative decisions 530
- proficiency testing (PT)
- antisperm antibody tests 609
- semen analysis 567, 574
- progesterone
- acrosomal exocytosis 111
- ovulation 367
- production in Leydig cells 34–35
- progesterin(s)
- male contraception 480, 481–82, 482–83
- testosterone contraception combination 480, 481–82
- progesterin challenge test 368
- prolactin 199, 433
- prolactinoma 433
- prolactin-secreting tumors 202
- pronephros 90
- propranolol, gonadotoxicity 238
- prostaglandin(s)
- empiric therapy 447–48
- seminal vesicle secretions 100
- varicocele 333
- prostaglandin E₁ (PGE₁) intracavernosal injection 139
- MUSE™ 139–40
- prostanoids 139
- prostate 98–100
- ejaculate composition 99–100
- ejaculation 142–43
- embryology 6, 91
- glandular 99
- midline cyst 387
- spinal cord injuries 465–66
- testosterone replacement therapy effects 208–09
- TRUS 380, 381, 424
- zones 99
- prostate cancer 99–100
- vasectomy association 479
- prostate massage 464
- prostate-specific antigen (PSA) 99–100
- prostatitis 296–97
- antisperm antibodies 283
- classification 296, 321
- leukocytospermia 321
- protamines 80
- deficiency 185
- DNA packaging 80
- gene expression 80–81
- sperm constituents 637
- protein phosphorylation, sperm capacitance 106–07
- proteomics 649
- provider liability, legal issues 535–37
- prune belly syndrome 264
- pseudoephedrine 458
- pseudohermaphroditism 260
- psychological issues 516–26
- assisted reproduction 519–25
- azoospermia 521
- donor insemination 523, 524
- epididymal sperm retrieval 521
- gamete donation 520–21, 521–22
- disclosure/nondisclosure 524–25
- medical team recommendations 523
- intracytoplasmic sperm injection 519–20, 522
- literature review 518–19

- medical team
 emotional factors 519
 gamete donation disclosure/
 nondisclosure 525
 IVF/ICSI recommendations 522
 recommendations 519, 522–23
 understanding 519
 microepididymal sperm retrieval
 521
 ovum donation 523–24
 reactions to infertility 516–18
 testicular sperm retrieval 521
 in-vitro fertilization 519–20, 522
 psychotherapeutic agents,
 gonadotoxicity 239–40
 psychotropic agents, ejaculation
 145
 PT-141 140
 pudendal nerve 132, 136, 143
P-value 543–44
 pyospermia 167–68
 cellular immunity 285
 leukocyte semen levels 170–71

 quality control
 antisperm antibody tests 608–10
 immunobead test 608–10
 semen analysis 566
 external 567
 quality management 551

 RAD51 protein 127
RAD18 gene 646
 radiolabeled antiglobulin assay 604
 radionuclide imaging, varicocele 339
 radiotherapy 156
 gonadotoxicity 238–39
 sperm collection for future
 insemination 598
 sperm retrieval 416–17
RBMX and *RBMV* genes 646
 reactive nitrogen species (RNS) 618,
 624
 reactive oxygen species (ROS) 311–14
 DNA damage 638
 DNA packaging 80
 ICSI outcome 506
 leukocyte effects 311–12, 313, 314
 Leydig cells 39–40
 measurement 171, 183–84
 overproduction 227
 semen 618–28
 chemiluminescence assay 619
 direct measurement 619
 generation 618–19
 indirect measurement 623
 levels 183–84, 506
 protocols 625–26
 ROS–TAC score 313–14, 625
 tests 619–24
 types 618
 sperm 184
 capacitance 106
 cryopreservation 594
 DNA damage 185
 effects 183
 steroidogenesis 39
 varicocele 334–35, 353–54
 vitamin therapy 449
 reactive oxygen species–total
 antioxidant capacity (ROS–
 TAC) score 313–14, 625
 receiver operating characteristic
 (ROC) curve 544–45, 547
 reciprocal translocations 508
 recombinant human follicle-
 stimulating hormone
 (rhFSH) 443
 redox environment, Leydig cells
 39–40
 redox potential GSH/GSSG 623
 5 α -reductase deficiency 205, 259–60
 regression to the mean 546–47
 regret feelings 517
 Reifenshtein syndrome 205–06
 relatives, surviving 536
 religious factors, gamete donation 524
 renal agenesis 264
 congenital absence of vas deferens
 387
 renal disorders, imaging 387
 renal metabolites, varicocele 333
 renal ultrasound, congenital absence
 of vas deferens 378
 renal vein, reflux 333
 reproductive history taking 154–55
 reproductive tract
 male 98
 sperm transport in female 104–08
 respiratory infections, chronic upper
 155–56
 retarded ejaculation 455–56
 rete testis 8–11
 cystic dilation 378
 dilated 384, 386
 tubular ectasia 384–85
 retinoic acid, spermatogenesis 65
 retinol, spermatogenesis 65
 retrogens 124
 retrograde ejaculation 163, 455–56
 alpha-blocker-induced 238
 simple wash 586–87
 sperm recovery 586
 treatment 459–60

 retroperitoneal lymph node dissection
 458, 459
 RhoA 136–37
 Rho-kinase 136–37
 pathway antagonism 140–41
 RNA, spermatozoa 128, 648
 RNA transcription
 change diagnosis 648–49
 expression microarrays 648
 spermatogenesis 128
 RNA translation modulation 647–48
 Robertsonian translocation 508
 aneuploidy rate 189
 sperm chromosome anomalies 188,
 190
 round cell counts 316, 613
 round spermatid nucleus injection
 (ROSNi) 510
 RPA protein 127
 r(Y) 256

 sacral parasympathetic nuclei, pro-
 erectile 134
 saline infusion sonohysterography 370
 saw palmetto 156–57
 sclerosing agents, varicocele 388–89
 sclerotherapy, varicocele 346
 antegrade 347, 355
 complications 355
 screening tests 544
 scrotal masses
 imaging 382–85
 malignant 385
 ultrasonography 382–85
 scrotal thermography, varicocele
 338–39
 scrotal ultrasound 376, 382–85
 epididymal obstruction 377
 scrotum
 examination in varicocele diagnosis
 336–37
 pain with varicocele 340
 temperature in varicocele 335
 second messengers, erectile function
 137
 secrecy, gamete donation 522
 Segre–Silberberg effect 554
 selective androgen receptor
 modulators (SARMs) 480, 483
 selective serotonin reuptake inhibitors
 (SSRIs)
 ejaculation 145–46
 gonadotoxicity 240
 premature ejaculation treatment
 146, 456, 459
 self, perceived deficit 520
 self-blame 517

Cambridge University Press

978-0-521-87289-8 - Infertility in the Male, Fourth Edition

Edited by Larry I. Lipshultz, Stuart S. Howards and Craig S. Niederberger

Index

[More information](#)

Index

- self-esteem loss 517
 self-shadowing of thymus 277
 semen
 abnormalities 161
 antioxidants
 determination 624–25
 nonenzymatic 625
 total capacity measurement 625
 ascorbic acid levels 431
 coagulation 159–60
 composition 550
 concentration 160
 density 544, 545–46
 ejaculation 104–05
 granulocytes 311
 hyperviscous 160, 167–68
 immune cells 307–11
 infertile men 313
 isolated defects 164
 leukocytes 307–11
 quantification 170–71
 liquefaction 99–100
 lymphocytes 307–08
 multiple variables 163–64
 normal parameters 162
 oxidative stress 618, 623
 biomarkers 628
 measurement 619
 physical characteristics 159–60
 postcoital test 160
 postoperative testing after
 vasectomy 477
 processing methods 584–89
 proteomics 649
 quality in spinal cord injuries
 465–66
 reactive nitrogen species 618
 determination 624
 reactive oxygen species 183–84, 506,
 618–28
 direct measurement 619
 generation 618–19
 indirect measurement 623
 protocols 625–26
 tests 619–24
 types 618
 reference ranges 159
 screening of donor 597–98
 spinal cord injuries 320–21, 465, 466
 quality 465–66
 viscosity 160
 volume defects 164–65
 white blood cell assay 613–15
 Bryan–Leishman stain 613
 dipstick tests 613
 flow cytometry 614
 granulocyte elastase test 614
 immunohistology 614, 615
 Papanicolaou stain 613
 peroxidase test 613, 615
 round cell counts 613
 semen analysis 158–61, 550–67
 automation 562–64
 benchmarks 566–67
 characteristics measured 559
 clinical chemistry reference range
 564
 collection 159, 551
 competency testing 567
 computer-assisted 161, 563
 debris content 552
 ejaculatory duct obstruction 423
 hematology reference range 564
 initial evaluation 551–52
 leukocytes 310–11, 552–53, 613–15
 leukocytospermia 553
 liquefaction 551–52
 macroscopic assessment 552
 mathematical 545–46
 microscopic examination 552–53
 optical density instruments 563
 parameters 565
 pH 552
 proficiency testing 567, 574
 prolactinoma 433
 quality control 556, 566–67
 external 567
 quality management 551
 reference ranges 564, 565
 results 550–51
 round cells 552–53
 sample handling 552
 sample mixing 552
 sperm agglutination 552
 sperm count 564
 manual 553–55
 quality control 566
 sperm morphology 556–62
 assessment 556
 classification 557–62
 methods 557
 quality control 566–67
 structure 574
 sperm motility
 manual assessment 555–56
 quality control 566
 SQA technology 563
 timing 551
 training 566
 video recordings 566
 weighing 552
 semen processing
 buffers 585
 density gradient centrifugation 589
 epididymal sperm retrieval 589
 equipment 584–85
 IVF/ICSI 589
 media 585, 586
 protein source 585
 oligospermia 589
 retrograde ejaculation sperm
 recovery 586
 simple centrifugation wash method
 585–86
 simple wash
 for cryopreserved specimens 586
 for retrograde ejaculate 586–87
 supplies 584–85
 swim-up, swim-down migration
 methods 587–88
 testicular biopsy 589
 testicular sperm retrieval 589
 semenogelin 551–52
 seminal fluid
 decapitating factors 583
 dilutional washing 286
 emission 144–45
 seminal vesicles 100
 atrophic 379
 congenital absence of vas deferens
 378
 cystic 381
 cystic dilation 381
 distended/dilated 380, 387, 425, 426
 ejaculatory volume 142
 mega 381
 midline cyst 380
 MRI 379
 proteins 100
 secretions 100
 size 423
 spinal cord injuries 465
 TRUS 378, 379, 380, 381
 seminal vesiculography 424
 seminiferous tubules 50
 germ cell maturation 75
 germinal epithelium 218–19
 histology 74–75
 hypoplasia 217–18
 obstruction 222
 spermatogenic cycles/waves 75
 testicular biopsy 217, 222
 seminoma, imaging 384
 serotonin 141
 ejaculation 145
 Sertoli cell(s) 8, 48
 actin filaments 50–51
 adherens junctions 56
 basement membrane 48
 basic helix-loop-helix transcription
 factors 57

- blood–testis barrier 55
 cytoskeletal architecture 50
 differentiation 57–58
 ectoplasmic specializations 52–53
 function regulation 57–58
 Golgi apparatus 51
 Id proteins 57–58
 immune function 307
 inhibin B 23, 480
 intermediate filaments 53–54
 microscopic structure 50
 microtubules 54–55
 peritubular myoid cell secreted
 mesenchymal factors 57
 protein secretion 62–65
 spermiation 56–57
 spermiogenesis 56–57
 SRY gene-induced differentiation 65
 structure 48–55
 testis development regulation
 65–66
 TGFs 53
 tight junctions 49, 56, 280
 tubulobulbar complexes 51–52
 ultrastructure 48
- Sertoli cell tumor, imaging 384
 Sertoli-cell-only syndrome 218, 219
 Sertoli-cell-specific knockout
 of androgen receptor
 (SCARKO) 83
- sex chromosome anomalies 644
 numerical 189–90
 sperm chromosome abnormalities
 188
- sex determination/development
 genetic disorders 260
- sex hormone-binding globulin
 (SHBG) 201
 conditions altering levels 201
- sex hormones, metabolic activation/
 inactivation 230–31
- sexual development disorders 260–62
 sexually antagonistic genes theory 123
 sexually transmitted diseases, donor
 semen screening 597–98
- short-chain aliphatic hydrocarbons
 232–34
- sildenafil 138, 449
 gonadotoxicity 240
see also phosphodiesterase type 5
 (PDE-5) inhibitors
- situs inversus 155–56, 157, 179, 267
 small interfering RNA (siRNA) 128
 smoking *see* cigarette smoking
- smooth muscle
 relaxation 137–38
 tone 138
- smooth-muscle myosin phosphatase
 (SMPP-1M) 136–37
- SNARE proteins, acrosomal
 exocytosis 111
- social factors
 donor gametes 524
 isolation 518
- somatic cell nuclear transfer 510
 somatic nervous system, ejaculation
 145
- SOX3 gene 123
 SOX9 gene 260–61
- SPARC (secreted protein acidic and
 rich in protein) 65
- SPATA16 gene mutation 266
- sperm/spermatozoa
 abnormal 551
 acrosomal abnormalities 577–78
 agglutination 166, 552
 antibody-mediated autoimmunity
 282
 antigenicity 282
 aspiration 95
 axoneme defects 179
 binding to zona pellucida 108–10
 calcium ion concentrations 107
 capacitation 104–05, 105–07,
 582–83
 in-vitro conditions 107
 cell-mediated autoimmunity
 284–85
 cervical deposition 582
 cervical mucus interaction 171,
 179–80
 chemotaxis 108
 cholesterol efflux 106
 chromatin 185
 chromosomally normal infertile
 men 190
- chromosome abnormalities
 fertile men 188–89
 sex-chromosome numerical
 anomaly carriers 189–90
 structural reorganization carriers
 190
- collection
 and freezing 528–29, 594–95 *see*
also (sperm cryopreservation)
 for future insemination 598–99
 kits 595
- concentration
 defects 165
 in epididymis 97
 IVF outcome 502
- density gradient centrifugation 589
 density in varicolectomy 348, 350
 DNA 185
- DNA damage 184, 185, 186
 reactive oxygen species 623–24
 reproductive outcomes 185–87
 tests 187
- DNA fragmentation tests 633
 DNA integrity testing 633–35
 donated 520–21
 egg interactions 105, 108–14
 electron microscopy 179
 emission 582
 enzymatic hydrolysis in zona
 pellucida penetration 112
- epididymal intraluminal
 concentration 97
- epididymal intraluminal
 environment exposure 96
- ESTs 128
- fertility 93–94, 95
- fertilization 104
- fibrous sheath dysplasia 179
- flagellum 74
 formation 81
 zona pellucida penetration
 111–12
- forward progression 160
- function genetic disorders 266–67
- fusion to oolemma 112–13
- head separation from tail 179
- HIV infection 432
- hyperactivation 104–05, 107
- image-guided retrieval 389
- immune response 277
- immune tolerance 281–82
- insemination of processed 583
- intracellular ion concentrations
 106, 107
- manual counting 553–55
- maturation 92–96 *see also*
 (maturation arrest)
 heat effects 486
 measures 93
- migration 587–88
- mixing in epididymis 95–96
- molecular genetic fingerprint 128
- morphology 160–61, 556–62
 abnormal 496, 560, 576,
 577–78
 ASCP classification 561, 574
 assessment 556, 575–76
 atlas discordance 564–65
 classification 557–62, 564–65,
 574, 576
 clinical relevance 577
 defects 167
 differential evaluation 576
 fertility link 576–77
 fertilization potential 578

Index

- sperm/spermatozoa *cont.*
 ICSI outcome 505–06, 577
 intrauterine insemination 577
 IVF 577
 Macleod system 560–61
 methods 557
 normal 561–62, 575–76, 577, 578
 prognostic value of strict criteria 577
 quality control 566–67
 slide preparation 575
 stains 575
 standardization 574
 strict classification 562
 strict criteria 574–78, 576
 structure 574
 variation 574
 varicoectomy 349, 353
 WHO classification 561, 562, 565, 574, 576
- motility 93, 104–05, 107
 axoneme defects 179
 cryopreserved 586
 defects 166–67, 178
 electron microscopy 179
 IVF outcome 502
 manual assessment 555–56
 measurement 160
 methods 560
 objective method 555–56, 557
 progressive score 555–56
 quality control 566
 spinal cord injuries 466
 varicoectomy 349, 352
- mycoplasma effects 298–302
 nonmotile 166–67
 persistence post-vasectomy 477–78
 normal 551, 566
 oocyte penetration interference 284
 opsonization 284
 oxidative damage 183
 penetration through zona pellucida 111–12
 persistence in ejaculate post-vasectomy 477–78
 pinheaded 179
 plasma membrane modifications 105–06
 precursors 554
 preparation techniques 584
 simple centrifugation wash method 585–86
 preparation techniques for IVF 501–02
 processing
 intrauterine insemination 584
 rationale 583–84
 techniques 582–90
- protamines 80
 constituents 637
 deficiency 185
 protein phosphorylation 106–07
 protein removal 106
 reactive oxygen species 106, 183, 184, 311–12, 312–14
 RNA 128
 genetic analysis 648
 spinal cord injuries 320–21
 motility 466
 retrieval 464
 storage in epididymis 91, 97–98, 142, 454
 structure 74
 tail formation 81
 thermotaxis 107–08
 total output 555
 transcriptome 127–28
 transport 96–97
 female genital tract 104–08, 582–83
 vas deferens 142, 454
Trichomonas vaginalis effects 303
 use of frozen 529
 viability tests 178–80, 505, 556, 558
see also acrosome; donor insemination
- sperm/spermatozoa receptors 106, 109–10
 sperm agglutination tests 604
 sperm antibodies 609
 female partner 607
 sperm antigen vaccine 484
 sperm banking 593
 applications 597
 azoospermia 599–600
 donor semen screening 597–98
 principles 593–94
 sperm collection for future insemination 598–99
see also cryopreservation; sperm cryopreservation
- sperm chromatin dispersion analysis 633, 637
 sperm chromatin structural assay (SCSA) 80, 633–35, 636–37
 sperm count 160, 564
 cryopreserved sperm 586
 historic decline 226
 manual 553–55
 quality control 566
 sperm cryopreservation 528–29, 594
 buffers 595–96
 cancer patients 239, 529
 cold shock minimizing 596
 collection methods 594–95
- cooling rate 593, 594
 damage 586
 donor semen screening 597–98
 equipment 597
 failure to maintain 536
 free radical scavengers 594
 freezing 586, 596–97
 rate 594, 597
 handling of sperm 594
 ICSI outcome 507
 intraoperative 394
 litigation 529
 media 595–96
 posthumous parenting 533–35
 principles 593
 regulation 597
 ROS formation 594
 simple wash 586
 specimen preparation 595–96
 sterile technique 595
 storage 596–97
 testicular sperm retrieval methods 595
 thawing 586, 596–97
 rate 597
 warming rate 593, 594
- sperm donor lab test panel 495
 sperm granuloma, vasectomy complications 478
 sperm immobilization tests 603
 sperm penetration assay (SPA) 113–14, 182
 IVF 502–03
 leukocyte effects 311
 sperm retrieval 407–18
 anesthesia 408
 cancer treatment 416–17
 chemotherapy 416–17
 cryptorchidism 417
 DNA fragmentation 417–18
 epididymal 409–12
 image-guided 389
 infectious disease testing 407
 Klinefelter syndrome 416
 minor male patients 533
 outcomes 415–16
 post-retrieval care 415
 pre-retrieval preparation 407–08
 radiotherapy 416–17
 spinal cord injuries 464
 success 415–16
 surgical 464–69
 surgical volume 417
 testicular 412–14
 testicular tissue processing 417
 vasal 408–09, 410
 Y-chromosome microdeletions 416

- sperm testing
 acrosome reaction assay 171, 180–82
 chromosome probes 188
 dye exclusion assays 178
 egg interaction in-vitro assays 113–14
 epididymal transit time 92
 FISH 188–91
 function evaluation 177
 functional assays 171
 hypo-osmotic swelling test 178
 intrauterine insemination 494
 sperm penetration assay 113–14, 182
 viability assays 178–80, 505, 556, 558
 viability stain 178
see also acrosome reaction assay; hemizona assay
- sperm washing 583–84
 immunologic infertility treatment 287
- spermatic cords, palpation 157–58
- spermatic vein, internal
 ligation 345–46
 reflux 338, 346
 valvular abnormalities 332
 varicocele 332
- spermatic venography
 retrograde 338
 varicocele imaging 375–76
- spermatids 77, 78
 cytoplasm loss 81
 DNA compaction 80–81
 maturation 56
 movement 54–55
 nuclear changes 80–81
 tubulobulbar complexes 51–52
- spermatocoele, imaging 383, 384
- spermatocytes
 apoptosis 79
 differentiation 58–59
 pachytene 126, 127
 secondary 78, 79
 types 75
- spermatogenesis 58–59, 439, 480
 abnormal sperm 577–78
 DNA damage 638
 adult 74–78
 cell types 75
 chemotherapy effects 239
 chromatid body 84
 chromosomal recombination 124–26
 abnormal in male infertility 126
 variations in normal men 126–27
 compounds targeting 486
 deficiency 255
- endocrine regulation 81–83
 fine needle aspiration mapping 217
 gene expression control 83–84
 germ cell-specific gene isoforms 83
 germ cell-specific promoter function 83–84
 gonadotropins 19, 59, 82
 heat effects 486
 hypothalamic–pituitary–gonadal axis 59, 60
 IL-1 regulation 61–62
 IL-6 regulation 62
 Kallmann syndrome 432–33
 LIF regulation 62
 maturation arrest 218
 MIWI genes in regulation 647–48
 paracrine regulators 61–62
 PIWI genes in regulation 647–48
 process 75–78
 recovery after chemotherapy 239
 regulation 58–65
 retinoic acid 65
 retinol 65
 RNA transcription 128
 stimulation with clomiphene 432
 testosterone 29, 257–58
 replacement therapy effects 208
 suppression by 483
 testosterone-rebound therapy 447
 TGF signaling 62
 X-chromosome gene mutations for failure 122
- spermatogenic cycles/waves 75
- spermatogonia 58, 75–76
 Ad cells 76–77
 Ap cells 76–77
 chemotherapy effects 238–39
 embryonic development 76
 fate regulation 77–78
 germ cell-specific X-linked genes 123
 mitosis 78
 primates 76
 self-renewal 76–77
 subpopulations 76
 types 75
- spermatogonial stem cells 58, 76, 649–50
 differentiation 77–78
 self-renewal 77–78
 transplantation 77
- spermiation 58–59, 79–80, 81
 Sertoli cells 56–57
 signal 81
- spermiogenesis 58–59, 79–80
 axoneme formation 81
 cytoplasm loss 81
- DNA compaction 80–81
 nuclear changes 80–81
 outer dense fibers 81
 regulation 81–82
 Sertoli cells 56–57
 tail formation 81
- SpermMar (SPMAR) test 605
 variability 608–09
- sperm–zona pellucida binding ratio test 113
- sperm–zona pellucida defective interactions 104
- spinal and bulbar muscular atrophy, X-linked 259
- spinal cord injuries
 accessory glands 465–66
 bulbocavernosus response 461–62
 cytokines 466
 ejaculation abnormalities 457, 465–69
 electroejaculation 463–64
 erectile dysfunction 454
 hip flexor response 461–62
 intracytoplasmic sperm injection 468–69
 intrauterine insemination 468
 intravaginal insemination 467
 leukocytospermia 320–21, 466
 penile vibratory stimulation 460, 461–62, 463–64
 prostate abnormalities 465–66
 reproductive options 466–69
 semen 320–21, 465, 466
 quality 465–66
 seminal vesicle abnormalities 465
 sperm 320–21
 motility 466
 retrieval 464
 in-vitro fertilization 468–69
- spinal dysraphism, ejaculation abnormalities 458
- spinal ejaculation generator 144
- spironolactone
 causing male infertility 430
 history taking 156
- splanchnic nerve, pelvic 457
- SRY gene 11, 90
 function 260–61
 location 253
 Sertoli cell differentiation 65
 testis differentiation 30
- SRY protein 8
- statistics 541–46
 multivariate 547
 regression to the mean 546–47

Index

- stem cells 649–51
 embryonic 649
 Leydig 32–34, 650–51
 aging 34
 techniques 649
see also spermatogonial stem cells
- stem-cell niche 77–78
- steric interference 284
- steroid abuse, testicular biopsy 223
- steroid biosynthesis pathway 230–31, 262
- steroid metabolism defects 259–60, 262
- steroid receptor superfamily 257
- steroidogenesis
 adult Leydig cells 34–38
 reactive oxygen species 39
- steroidogenic acute regulatory protein (StAR) 19, 37–38, 256–57
 cholesterol transport 36, 37
 function 37–38
- steroidogenic factor 1
- stimulated acrosome reaction (SAR) 181
- stress 517–18
- strict classification of sperm morphology 562
 criteria 574–78
- stroke, ejaculation abnormalities 458–59
- stump tail syndrome 179
- subfertile male
 azoospermia 162–63
 diagnostic categories 171
 diagnostic evaluation 203
 history taking 154–55, 155–58
 initial evaluation interpretation 161–68
 laboratory testing
 additional tests 168–71
 initial 158–61
 office evaluation 153–54
 physical examination 157–58
- subparafascicular thalamic nucleus 144
- substance P 143
- subzonal insertion of sperm (SUZI) 500, 503, 504
- sulfasalazine 240
- superoxide anion 183
 cytochrome c reduction test 620
- superoxide dismutase (SOD) 183, 625
 sperm cryopreservation 594
- surgical history 156
- surgical volume, sperm retrieval 417
- swim-down technique 587
- swim-up technique 587–88
- sympathetic nervous system, ejaculation 145
- sympathetic nuclei, erectile function 136
- synaptonemal complex (SC) 124–25
 azoospermia 126
 nonexchange 127
 pachytene spermatocytes 126, 127
- synaptonemal complex proteins (SCPs) 78, 125
- syncytium, functional 137
- syphilis, donor semen screening 597–98
- systemic disease 155–56
 hypogonadotropic hypogonadism 203
- systemic immunity 281
- systemic immunosuppression 286
- T lymphocytes, activated in spinal cord injury 466
- tadalafil 138
 gonadotoxicity 240
see also phosphodiesterase type 5 (PDE-5) inhibitors
- tamoxifen citrate 441, 442
- tamsulosin 459
- targeted therapy 432–34
- teratoma, imaging 384
- teratozoospermia 167
 sperm transport failure 583
- TEST-CII 595–96
- testes 2, 92
 apoptosis 227
 atrophy 162–63
 basement membrane 51
 blood supply in microsurgical reconstruction 403
 blood–testis barrier 55–56
 cell death 226–28
 cell necrosis 227
 cellular dysfunction mechanisms 226–28
 cellular injury mechanisms 226–28
 descent 11, 261, 262 *see also* (cryptorchidism)
 development 10, 11
 differentiation 30
 hormone imbalance 227–28
 hyperthermia 240
 IGF-1 production 24
 immunology 279–82
 lamina propria 51
 malignancy 384
 microlithiasis 386
 microscopic structure 49
 microscopy 217
 pathology in varicocele 335–36
 peroxidative damage 227
- physical examination 157–58, 200
- proteomics 649
- Sertoli cell regulation of development 65–66
- size in varicocele 340–41
- sperm retrieval 412–14
- testosterone
 production 22
 replacement therapy effects 208
- tissue cryopreservation 594
- tissue processing for sperm retrieval 417
- trauma 155
- tumor 384
- undescended 382
- vasectomy changes 393–94
- venogram 388
- volume measurement 157–58, 200
see also cryptorchidism; varicocele
- testicular artery, ligation 346
- testicular biopsy 215
 aging 223
 anabolic steroids 223
 andropause 223
 azoospermia 221–22
 cryptorchidism 223
 cytological assessment 217
 DNA damage 220
 end-stage change 218–19
 fine needle aspiration 216–17
 FISH 220
 flow cytometry 220
 germinal epithelium 218–19
 hypogonadism 223
 indications 221–22
 Johnsen scoring system 221
 light microscopy 217
 malignancy 219–20, 222
 near-red confocal imaging 223
 novel analysis techniques 220
 oligospermia 222
 optical coherence tomography 223
 partial orchiectomy 222
 pathological classification 217–20
 percutaneous 216–17, 584
 scoring schema 220–21
 semen processing 589
 seminiferous tubule obstruction 222
 standard open surgical 216
 steroid abuse 223
 techniques 215–17
 testicular sperm extraction 216
 touch prep techniques 217
 tubular architecture 217
 tunica albuginea incision 216
 varicocele 222–23
 wet-prep cytological assessment 217

- testicular cancer 156, 219–20
 sperm collection for future
 insemination 598–99
 vasectomy association 479–80
- testicular cysts, imaging 384–85
- testicular dysgenesis syndrome 219,
 228
 phthalates 236
- testicular feminization 205–06, 258
- testicular hypothermia device 347
- testicular mapping 413
- testicular microlithiasis
 germ cell tumors 386
 imaging 385–86
- testicular sperm aspiration (TESA)
 414, 584
 sperm cryopreservation 595
- testicular sperm extraction (TESE)
 216, 412–13, 584
 Klinefelter syndrome 252
 MESA failure 410, 411
 sperm cryopreservation 595
see also microdissection testicular
 sperm extraction (micro-
 TESE)
- testicular sperm retrieval 412–14
 methods 595
 psychological issues 521
 semen processing 589
- testicular torsion 155
- testicular tumors 200
- testicular vein, reflux 338
- testis-determining factor (TDF) 90
- testolactone 441, 442–43
- testosterone 8–11, 480
 adult Leydig cell production 32,
 34–38
 aging effects 29, 38–39
 circulating level decline 206, 207
 clomiphene citrate effects 440
 exogenous 447
 free 201
 GnRH analog combination 483
 GnRH secretion regulation 17–18
 gonadotropin feedback
 regulation 20
 gonadotropin role in secretion 19
 hypothalamic–pituitary–gonadal
 axis 22–23
 male contraception 480–81, 483
 combination use 480, 481–82,
 483
 measurement 169–70
 in azoospermia 162–63
 normal male development role
 257
 plasma levels 22–23
- progesterin contraception
 combination 480, 481–82
- rebound therapy 447
- role 256
- serum levels 30
- side effects 481
- spermatogenesis 29, 257–58
 regulation 82
 suppression 483
- testicular descent 11, 262
- varicocele 334
- testosterone buciate 481
- testosterone enanthate 480–81
- testosterone replacement therapy
 207–09, 237
 baseline evaluation 203
 buccal 207
 contraindications 208
 dosing 207–08
 formulations 207–08, 209
 hepatotoxicity 209
 hypogonadotropic hypogonadism
 therapy 205
 intramuscular 207
 monitoring 208
 oral 207
 over-the-counter 209
 side effects 208–09
 transdermal 208–09
- testosterone undecanoate 481
- testosterone–androgen receptor
 complexes 91
- TES–TRIS–citrate–yolk–glycerol
 mixture (TEST-CII) 595–96
- thermal cautery 476
- thermotaxis in sperm 107–08
- thiobarbituric acid-reactive
 substances (TBARS) 623
- thymus, self-shadowing 277
- tight junctions
 blood–testis barrier 55, 56
 ductuli efferentes 280–81
 Sertoli cells 49, 56, 280
- tobacco use
 causing male infertility 431
see also cigarette smoking
- total antioxidant capacity
 measurement 625
 protocol 626
- transferrin, Sertoli cell secretion
 64–65
- transforming growth factor (TGF) 24
 blood–testis barrier 55–56
 Sertoli cells 53
- transforming growth factor β (TGF- β)
 superfamily 63
 glial-derived neurotropic factor 78
- signaling in spermatogenesis 62
- transrectal ultrasonography (TRUS)
 ejaculatory duct cysts 380
 ejaculatory duct obstruction 165,
 421, 423–24
 partial 381–82
- ejaculatory duct stenosis 380
- epididymal obstruction 377
- prostate 380, 381, 424
- seminal vesicle 378, 379, 380, 381
- transurethral resection of ejaculatory
 duct (TURED) 425–27
 complications 426–27
 ejaculatory duct
 cysts 387, 426
 partial obstruction 381–82
 success rate 426
 treatment guidance 387–88
- trauma, ejaculatory duct obstruction
 393
- traumatic brain injury, ejaculation
 abnormalities 458–59
- trazodone 141
- treatment
 definition of successful 519
 empiric therapy 438–49
 targeted therapy 432–34
- 1,1,1-trichloro-2,2 α -bis
 (*p*-chlorophenyl) ethane *see*
 DDT exposure
- 2,4,5-trichlorophenol (TCDD)
 exposure 232
- Trichomonas vaginalis* 303
- urethritis 295
- tricyclic antidepressants,
 gonadotoxicity 240
- trigone 6
- Tripterygium wilfordii* 486
- trisomies 189, 644
- TSPO translocator protein 35–37
 cholesterol transport 36
 function 37–38
- tubulobulbar complexes, Sertoli cells
 51–52
- tumescence 133–34
 central control 134
 nocturnal 134
see also detumescence
- tumor necrosis factor (TNF) 285
- tumor necrosis factor α (TNF- α)
 315
- TUNEL assay 633, 635, 636–37
- tunica albuginea 11, 132
 cyst imaging 384–85
 incision 216
- Turner syndrome 256, 644
- type II error 544

Index

- ultrasonography
 color-flow Doppler 338, 375, 376–77
 congenital absence of vas deferens 378
 cryptorchidism 382
 distal inflammatory stenosis of ejaculatory ducts 380
 epididymal cysts 378
 epididymal obstruction 377
 hydrocele 383
 median cysts 380
 scrotal masses 382–85
 scrotum 376
 testicular microlithiasis 385–86
 varicocele 337–38, 376–78
 color-flow Doppler 338, 375, 376–77
- ultrasound, high-frequency, percutaneous vasectomy 476
- unexplained infertility 162
 DNA damage tests 187
- Ureaplasma urealyticum* 298–302, 432
- ureteric bud 2
- urethra 99, 143
 embryology 6
- urethral distension 144
- urethral meatus 143
- urethritis 295–96
Chlamydia trachomatis 295, 431
 gonococcal 295, 297
 nongonococcal 295, 297–98, 298–302
- urinalysis, postejaculate 164–65
- urinary ductal system development 1–2
- urogenital membrane 11
- urogenital sinus 5, 7
 development 91
 female 6–8, 9
 male 6
- urogenital tract, embryology 90–91
- uteroovaginal canal 7–8
- uterus
 embryology 7–8
 evaluation techniques 370
 female infertility 370
- vagina
 development 11
 embryology 7–8
- Valsalva maneuver, varicocele 158, 336
- vardeafil 138
 gonadotoxicity 240
see also phosphodiesterase type 5 (PDE-5) inhibitors
- variance components analysis 608
- varicella zoster virus 303
- varicocele 331–56
 adjuvant hormone therapy 354
 adolescent 340–41
 angioembolization 388
 antisperm antibodies 283
 apoptosis 335
 balloon embolization 346, 347, 355
 bilateral 332, 333
 cadmium levels 335
 catch-up growth 340–41
 coil therapy 346, 388–89
 color-flow Doppler ultrasonography 338, 375, 376–77
 diagnosis 336–39
 DNA fragmentation 334–35, 354
 Doppler examination 337
 embolization 346–47, 388
 angiographically-guided 388–89
 balloon 346, 347, 355
 complications 355
 external cremasteric system 332–33
 grading system 336
 historical perspective 331–32
 hormonal dysfunction 333–34
 adolescents 341
 hyperthermia 335
 hypothalamic–pituitary–gonadal axis 334
 hypoxia 334–35
 imaging 375–77
 incidence 331
 prepubertal 340
 internal spermatic vein 332
 intrauterine insemination use 496
 ligation 340
 Nagler maneuver 336
 nonsurgical treatment 346–47
 complications 355
 outcome analysis 347–54
 oxidative stress 334–35
 pampiniform plexus 331, 332–33
 pathology 335–36
 pathophysiology 333
 pediatric 340–41
 future fertility 342
 percutaneous angioembolization 388–89
 percutaneous venous occlusion 346–47
 physical examination 158, 336–37
 prognosis 347–51
 prognostic variables 351–54
 radionuclide imaging 339
 recurrent 344, 355
 reflux quantification 377
 renal metabolites 333
 ROS 334–35, 353–54
- sclerosing agents 388–89
- sclerotherapy 346
 antegrade 347, 355
 complications 355
- scrotal pain 340
- scrotal temperature 335
- scrotal thermography 338–39
- secondary infertility 342
- spermatic venography 375–76
- subclinical 337–38
- testes
 biopsy 222–23
 mass loss 340–41
 pathology 335–36
 size 340–41
- testicular hypothermia device 347
- therapeutic implications of repair 339–40
- treatment complications 354–55
- ultrasonography 337–38, 376–78
- Valsalva maneuver 336
- venography 338
- varicolectomy 331, 332, 342–46
 adjuvant hormone therapy 354
 anatomy 332–33
 azoospermia 353, 354, 355
 cosmesis 342
 etiology 332–33
 inguinal approach 343–44
 laparoscopic approach 345–46
 modified Ivanissevich approach 343–44
 modified Palomo approach 344–45
 outcome 347–51
 pregnancy rate 348, 351–53
 prepubertal 340–41
 noninfertility indications 342
 prognostic variables 351–54
 recurrence rate 354–55
 retroperitoneal approach 343, 344–45
 scrotal approach 342
 sperm
 density 348, 350
 morphology 349, 353
 motility 349, 352
 subinguinal approach 342–43, 344
 testicular changes 336
 therapeutic implications 339–40
- vas deferens
 anastomosis to epididymis 400
 complex reconstructions 398–99
 development 90–91
 function 392
 microsurgical reconstruction 395
 length for 402
 obstruction

- crossover procedure 399
 inguinal hernia childhood
 repair 398
 sperm retrieval 409
 occult injury 398–99
 sperm retrieval 408–09, 410
 sperm transport 142, 454
 unsuccessful vasectomy
 reversal 399
see also congenital bilateral absence
 of vas deferens (CBAVD)
- vasal agenesis 264
 vasal disease, bilateral 264
 vasal occlusion methods 476–78
 vasal sperm retrieval 408–09, 410
 vasectomy 474–80
 antisperm antibodies 283, 478
 formation 222
 cardiovascular disease 478–79
 complications 478
 ejaculatory duct obstruction 393
 failure 476–78
 hemoclips 476
 histological evaluation 475–76
 incision 474, 475
 intraluminal occlusion 476
 intra-vas device 476
 local anesthesia 474–75
 long-term effects 478–80
 needle electrocautery 476
 no-scalpel 475
 outcome 477
 percutaneous 476
 postoperative semen testing 477
 pressure-induced damage 478
 prostate cancer association 479
 recanalization incidence 476
 reversal 394, 474
 costs 509
 sperm collection for future
 insemination 598–99
 sperm persistence in ejaculate 477–78
 standard of care for sending
 specimens 476
 suture ligature 476
 systemic effects 478
 technical aspects 474–75
 testicular cancer association 479–80
 testicular changes 393–94
 thermal cautery 476
 vasal occlusion methods 476–78
 vasoactive intestinal peptide (VIP)
 ejaculation 145
 erectile function 137–38
 intracavernosal injection 140
 vas deferens innervation 142
 vasoepididymostomy 92, 93–94,
 394–95, 400–02
 end-to-end 401
 end-to-side 401
 intussusception 401–02
 outcomes 403
 results 402
 sperm fertility 93–94
 sperm maturation 94–95
 technique 400–02
 vasography 163
 ductal obstruction 394
 ejaculatory duct obstruction 423
 internal ring obstruction 399
 vasovasostomy 394–95, 395–400
 fibrin glue use 398
 modified one-layer 396
 multilayer 396–97, 399
 results 399–400
 robotic-assisted 397–98
 series 400
 single-layer 399
 success rate factors 399
 technique 395–96
 vasal fluid quality 399–400
 venography
 testes 388
 varicocele 338
 verumontanum 422
 vibrators *see* penile vibratory
 stimulation (PVS)
- vimentin 53
 virilization pattern 157
 vitamin therapy 447, 449
 voltage-dependent anion channel
 (VDAC) protein 37
- white blood cells *see* leukocytes;
 semen, white blood cell assay
- Wilms tumor suppressor gene (Wt-1)
 260
- Wnt* genes 90–91
 Wolffian ducts 2, 8–11, 90
 cysts 422, 425
 development 91
 differentiation 90
- women, psychological response to
 infertility 518
- World Health Organization
 (WHO), sperm morphology
 classification 561, 562,
 565, 574
- X chromosome 122–24
 clinical studies 122–23
 gene mutations for spermatogenic
 failure 122
 male fertility role 123–24
 mouse studies 122
- xenobiotics 434–35
- X-linked genes 123
 clinical studies 123
- 46,XX male syndrome 253
- xylenol orange-based assay
 621–23
- 47,XXY karyotype *see* Klinefelter
 syndrome
- 47,YYY karyotype 253
- Y chromosome 11, 90, 643
 duplications 645–46
 isodicentric 256
 molecular geography 253–55
 mosaic 256
- Y-chromosome microdeletion
 analysis 256
 nonobstructive azoospermia
 162–63
- Y-chromosome microdeletions
 253–56, 508, 643,
 645–46
- oligospermia 494
 sperm retrieval 416
- yohimbine 140
- Young syndrome 155–56, 264
- ZFX* gene mutations 123
- zidovudine (AZT) 305–07
- zinc, empiric therapy 449
- zona drilling 500, 504
 assisted hatching 509
- zona pellucida 104, 108–09
 changes after gamete fusion 113
 immunocontraceptives
 484–85
 proteins interacting 484–85
 role 109
 sperm binding to 108–10,
 109–10
 sperm penetration 111–12
 sperm receptors 109–10
 see also hemizona assay
- zona pellucida glycoproteins 109
- acrosomal exocytosis 110–11
- zygote 1
- zygote intrafallopian transfer
 (ZIFT) 503